Use of FLT3 car-t cells and FLT3 inhibitors to treat acute myeloid leukemia

JP2024120909A5Inactive Publication Date: 2024-12-03JULIUS MAXIMILIANS UNIV WURZBURG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024091613
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-08-01
Filing Date
2024-06-05
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for acute myeloid leukemia (AML) using FLT3 inhibitors are limited by resistance development and suboptimal antibody-mediated effector functions due to low antigen density, necessitating innovative strategies to enhance FLT3 targetability and efficacy.

Method used

Combining FLT3-specific chimeric antigen receptor (CAR)-engineered T cells with FLT3 inhibitors like midostaurin, quizartinib, or crenolanib to increase FLT3 expression on AML blasts, thereby enhancing recognition and elimination by CAR-T cells.

Benefits of technology

The combination therapy significantly increases FLT3 expression on AML blasts, leading to enhanced cytolytic activity, cytokine secretion, and prolonged persistence of CAR-T cells, resulting in superior antileukemic effects compared to monotherapy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide the treatment of cancer with FLT3 targeting agents and kinase inhibitors.SOLUTION: The present invention provides the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to the treatment of cancer with FLT3-targeted drugs and kinase inhibitors. In particular, the present invention relates to adoptive immunotherapy of acute myeloid leukemia (AML) using chimeric antigen receptor (CAR)-modified T cells specific for FLT3-like tyrosine kinase (FLT3) in combination with an FLT3 inhibitor. [Background technology]

[0002] FMS-like tyrosine kinase 3 (FLT3) is a type I transmembrane protein that plays a key role in normal hematopoiesis and is physiologically expressed in normal hematopoietic stem cells (HSCs) as well as lymphoid, myeloid, and granulocyte / macrophage progenitor cells in humans. 1~4 Among mature hematopoietic cells, FLT3 expression has been reported in subsets of dendritic cells and natural killer cells. 5~7 FLT3 is also uniformly present on malignant blast cells in acute myeloid leukemia (AML), providing a target for antibody and cellular immunotherapy. 1、4、8~11 The antigen density of FLT3 protein on the cell surface of AML blasts ranges from hundreds to thousands of molecules per cell, which is optimal for recognition by engineered T cells equipped with synthetic chimeric antigen receptors (CARs). 12、13 .

[0003] At the molecular level, FLT3 transcripts are ubiquitously detectable in AML blasts, and expression levels are graded into distinct FAB (French-American-British) subtypes. 9、14 High FLT3 transcript levels correlate with higher white blood cell counts and greater bone marrow infiltration by leukemic cells, independent of the presence of FLT3 mutations. 11 FLT3 is important for the survival and proliferation of AML blasts and is of particular pathophysiological relevance in AML cases that harbor activating mutations in the FLT3 intracellular domain. 1、11Of these, internal tandem duplications (ITDs) in the juxtamembrane domain and mutations in the intracellular tyrosine kinase domain (TKD) are the most common abnormalities, collectively occurring in approximately 30% of AML cases. 1、11、14、15 Both abnormalities result in constitutive FLT3 activation in a ligand-independent manner and act as gain-of-function "driver mutations" that contribute to the persistence of malignant disease. 16~18 These characteristics make FLT3-ITD + AML is particularly susceptible to anti-FLT3 immunotherapy, and FLT3 - / low The predicted risk of developing antigen-deficient AML blast variants is low, suggesting that this may indeed be a favorable AML subset. Indeed, the presence of FLT3-ITD is associated with poorer clinical outcomes after induction / consolidation chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), defining a subset of high-risk AML patients in need of novel innovative therapeutic strategies. 19、20 .

[0004] FLT3 has been pursued as a target for tyrosine kinase inhibitors, with a number of agents in advanced stages of clinical development. However, the clinical efficacy of monotherapy with "first-generation" FLT3 inhibitors has been significantly limited, due at least in part to the emergence of resistance due to de novo mutations in the FLT3 intracellular domain or to FLT3 overexpression in AML blasts. 21~25 .

[0005] Monotherapy with TKI can produce measurable clinical responses, including significant reductions in peripheral blood (PB) blasts and bone marrow (BM) blasts.However, in most cases, patients become resistant after a transient response, which is known as secondary resistance development.The emergence of new mutations in tyrosine kinase and / or juxtamembrane domains (primary resistance) after treatment with TKI has been frequently observed, which limits the clinical activity of TKI as monotherapy in refractory and relapsed AML patients.

[0006] Midostaurin is a "first generation" FLT3 inhibitor, a derivative of the alkaloid staurosporine, and a multi-targeted kinase inhibitor. Midostaurin inhibits FLT3, platelet-derived growth factor receptor (PDGFR) alpha and beta, cyclin-dependent kinase 1 (cdk1), src, Fgr, Syk (spleen tyrosine kinase), c-kit, and the major vascular endothelial growth factor (VEGF) receptor, KDR. Midostaurin is a type II FLT3 inhibitor that has shown activity against mutant FLT3 in vitro and in vivo (References 21-23).

[0007] Quizartinib (AC220) is a "first-generation" FLT3 inhibitor designed specifically for FLT3. Quizartinib is a type II FLT3 inhibitor and is used to treat FLT3-ITD. + Quizartinib has demonstrated activity against AML. Quizartinib has been shown to treat relapsed FLT3-ITD after stem cell transplantation or failure of salvage chemotherapy. + It has been shown to significantly improve overall survival in patients with AML (Reference 21).

[0008] Crenolanib is a specific type I inhibitor that targets the active FLT3 kinase conformation and is effective against FLT3 with ITD and TKD mutations that confer resistance to type II inhibitors that target the inactive kinase conformation, such as midostaurin and quizartinib. 26、27 Crenolanib is also active against the platelet-derived growth factor receptor alpha / beta and is being evaluated in patients with gastrointestinal stromal tumors and gliomas. 28、29 In AML, crenolanib has been proven to be effective in relapsed / refractory AML with FLT3-ITD and TKD mutations, and the response rate in a recently reported phase II clinical trial was noteworthy. 30、31 Therefore, crenolanib and other TKIs are being investigated in combination regimens to enhance efficacy.

[0009] FLT3 has also been explored as a target for antibody immunotherapy, even though the antigen density of FLT3 on AML blasts is much lower than that of, for example, CD20 on lymphoma cells, and is presumably not optimal for inducing potent antibody-mediated effector functions. 12 The murine anti-human FLT3 monoclonal antibody (mAb) 4G8 has been shown to bind specifically to AML blasts and to a lesser extent to normal HSCs, and to confer specific reactivity to AML blasts with high FLT3 antigen density in preclinical models after Fc-optimization. 14 . Summary of the Invention [Problem to be solved by the invention]

[0010] The inventors engineered T cells to express a FLT3-specific CAR with a targeting domain derived from 4G8 mAb and compared FLT3 wild-type and FLT3-ITD T cells to FLT3 CAR-T cells. + Anti-leukemic reactivity against AML cells will be analyzed alone and in combination with the FLT3 inhibitors midostaurin, quizartinib, and crenolanib. Furthermore, we will evaluate the recognition of normal HSCs as a predicted side effect of effectively targeting FLT3 to identify clinical situations for adoptive immunotherapy with FLT3 CAR-T cells in the context of allogeneic HSCT. [Means for solving the problem]

[0011] The present invention generally relates to the treatment of cancer with FLT3-targeting agents, particularly immunotherapy-targeting agents and kinase inhibitors. In particular, the present invention relates to the treatment of acute myeloid leukemia (AML) with T cells, preferably genetically modified to express a combination of FLT3-specific chimeric antigen receptors (CARs) and FLT3 inhibitors. The present invention demonstrates that treatment of AML blasts with FLT3 inhibitors leads to a significant increase in the expression of FLT3 molecules on the cell surface of AML blasts, which in turn leads to a significant increase in recognition and elimination by FLT3 CAR-T cells. The combination treatment of AML with FLT3-targeting agents, particularly CAR-T cells, and kinase inhibitors, particularly FLT3 inhibitors, is highly synergistic and superior to monotherapy with either FLT3 inhibitors or FLT3 CAR-T cells alone.

[0012] The present invention is illustrated by the following preferred embodiments: 1. A composition for use in a method for treating cancer in a patient, comprising: (a) a kinase inhibitor, and (b) FLT3 targeting drug Including, In this method The composition is administered to a patient. 2. The composition according to item 1 for the use as defined in item 1, wherein the method is a method comprising adoptive immunotherapy. 3. The composition according to item 1 or 2, for the use as defined in item 1 or 2, wherein the FLT3 targeting agent is capable of binding to the extracellular domain of FLT3. 4. The composition according to any one of items 1 to 3, for the use as defined in any one of items 1 to 3, wherein the FLT3 targeting agent inhibits the growth of cells expressing FLT3. 5. The composition according to any one of items 1 to 4, for the use as defined in any one of items 1 to 4, wherein the FLT3 targeting agent comprises a cell targeting agent that targets FLT3. 6. The composition according to item 5, for the use as defined in item 5, wherein the cell is a cell expressing a chimeric antigen receptor. 7. The composition according to item 6, for the use according to item 6, wherein the chimeric antigen receptor is capable of binding to FLT3. 8. The composition according to any one of items 5 to 7, for the use as defined in any one of items 5 to 7, wherein the cell is a cell selected from the group of a T cell, a NK cell, and a B cell. 9. The composition according to any one of items 5 to 8, for the use as defined in any one of items 5 to 8, wherein the cell is a T cell. 10. The composition according to any one of items 6 to 9 for the use as defined in any one of items 6 to 9, wherein the chimeric antigen receptor comprises the sequence SEQ ID NO: 2 or a sequence that is at least 90% identical to that sequence, or wherein the chimeric antigen receptor comprises the sequence SEQ ID NO: 4 or a sequence that is at least 90% identical to that sequence. 11. The composition according to item 10, for the use as defined in item 10, wherein the chimeric antigen receptor comprises the sequence SEQ ID NO: 2 or a sequence which is at least 90% identical to that sequence. 12. The composition according to item 10, for the use as defined in item 10, wherein the chimeric antigen receptor comprises the sequence of SEQ ID NO: 4 or a sequence which is at least 90% identical to that sequence. 13. The composition according to any one of items 6 to 12, for the use as defined in any one of items 6 to 12, wherein the chimeric antigen receptor comprises a heavy chain variable domain sequence of SEQ ID NO: 5 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 6 or a sequence that is at least 90% identical to that sequence, or wherein the chimeric antigen receptor comprises a heavy chain variable domain sequence of SEQ ID NO: 7 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 8 or a sequence that is at least 90% identical to that sequence. 14. The composition according to item 13, for the use as defined in item 13, wherein the chimeric antigen receptor comprises a heavy chain variable domain sequence of SEQ ID NO: 5 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 6 or a sequence that is at least 90% identical to that sequence. 15. The composition according to item 13, for the use as defined in item 13, wherein the chimeric antigen receptor comprises a heavy chain variable domain sequence of SEQ ID NO: 7 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 8 or a sequence that is at least 90% identical to that sequence. 16. The composition according to any one of items 1 to 4, for the use as defined in any one of items 1 to 4, wherein the FLT3 targeting agent comprises a protein. 17. The composition according to item 16, for the use as defined in item 16, wherein the protein is an antibody or a fragment thereof capable of binding to FLT3. 18. The composition according to item 17, for the use as defined in item 17, wherein the antibody or fragment thereof comprises a heavy chain variable domain sequence of SEQ ID NO: 5 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 6 or a sequence that is at least 90% identical to that sequence, or wherein the antibody or fragment thereof comprises a heavy chain variable domain sequence of SEQ ID NO: 7 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 8 or a sequence that is at least 90% identical to that sequence. 19. The composition according to item 18, for the use as defined in item 18, wherein the antibody is an antibody comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:6. 20. The composition according to item 18, for the use as defined in item 18, wherein the antibody is an antibody comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8. 21. The composition according to any one of items 1 to 20, for the use as defined in any one of items 1 to 20, wherein the kinase inhibitor is a multi-targeted kinase inhibitor. 22. The composition according to any one of items 1 to 21, for the use as defined in any one of items 1 to 21, wherein the kinase inhibitor is a tyrosine kinase inhibitor. 23. The composition according to any one of items 1 to 22, for the use as defined in any one of items 1 to 22, wherein the kinase inhibitor is an FLT3 inhibitor. 24. The composition according to any one of items 1 to 23, for the use as defined in any one of items 1 to 23, wherein the kinase inhibitor is a kinase inhibitor capable of causing upregulation of FLT3 in said cancer. 25. The composition according to any one of items 1 to 24, for the use as defined in any one of items 1 to 24, wherein the kinase inhibitor is a kinase inhibitor capable of causing upregulation of FLT3 cell surface expression in said cancer. 26. The composition according to any one of items 1 to 25, for the use as defined in any one of items 1 to 25, wherein the kinase inhibitor is a kinase inhibitor capable of causing upregulation of mutated FLT3 in said cancer. 27. The composition according to any one of items 1 to 26, for the use as defined in any one of items 1 to 26, wherein the kinase inhibitor does not cause upregulation of wild-type FLT3 in said cancer. 28. The composition according to item 26, for the use as defined in item 26, wherein the mutated FLT3 comprises a mutated tyrosine kinase domain and / or the mutated FLT3 comprises an internal tandem duplication. 29. The composition according to item 28, for the use according to item 28, wherein the mutated FLT3 comprises an internal tandem duplication. 30. The composition according to item 28, for the use according to item 28, wherein the mutated FLT3 comprises a mutated tyrosine kinase domain. 31. The composition according to any one of items 1 to 30, for the use as defined in any one of items 1 to 30, wherein the kinase inhibitor does not inhibit T cells expressing a chimeric antigen receptor. 32. The composition according to any one of items 1 to 31, for the use as defined in any one of items 1 to 31, wherein the kinase inhibitor is a type I or type II FLT3 inhibitor. 33. The composition according to item 32, for the use as defined in item 32, wherein the kinase inhibitor is a type I FLT3 inhibitor. 34. The composition according to item 32, for the use as defined in item 32, wherein the kinase inhibitor is a type II FLT3 inhibitor. 35. The composition according to any one of items 1 to 32, for the use as defined in any one of items 1 to 32, wherein the kinase inhibitor is selected from the group consisting of crenolanib, midostaurin, and quizartinib. 36. The composition according to item 35, for the use as defined in item 35, wherein the kinase inhibitor is crenolanib. 37. The composition according to item 35, for the use as defined in item 35, wherein the kinase inhibitor is quizartinib. 38. The composition according to item 35, for the use as defined in item 35, wherein the kinase inhibitor is midostaurin. 39. The composition according to any one of items 1 to 38, for the use as defined in any one of items 1 to 38, wherein treatment of said cancer has an improved clinical outcome compared to treatment with a monotherapy using either the FLT3 targeted agent or the kinase inhibitor alone. 40. The composition according to any one of items 1 to 39, for the use as defined in any one of items 1 to 39, wherein the FLT3 targeted agent and the kinase inhibitor extend the progression free survival of the patient as compared to monotherapy with either the FLT3 targeted agent or the kinase inhibitor alone. 41. The composition according to any one of items 5 to 40, for the use as defined in any one of items 5 to 40, wherein, when administered to a patient, the cells produce effector cytokines. 42. The composition according to item 41, for the use as defined in item 41, wherein the cytokines are IFN-gamma and IL-2. 43. The composition according to any one of items 1 to 42, for the use as defined in any one of items 1 to 42, wherein the cancer is leukemia or lymphoma. 44. The composition according to item 43, for the use as defined in item 43, wherein the cancer is leukemia. 45. The composition according to item 44, for the use as defined in item 44, wherein the leukemia is mixed lineage leukemia or acute lymphoblastic leukemia. 46. ​​The composition according to item 44, for the use as defined in item 44, wherein the leukemia is acute myeloid leukemia. 47. The composition according to any one of items 1 to 46, for the use as defined in any one of items 1 to 46, wherein the method is a method for increasing the number of FLT3 molecules on the cell surface, preferably increasing the number of FLT3 molecules on the cell surface of a cancer cell. 48. The composition according to item 47, for the use according to item 47, wherein FLT3 upregulation is caused by treatment with said kinase inhibitor. 49. The composition according to item 48, for the use as defined in item 48, wherein the cancer has acquired resistance to monotherapy treatment with the kinase inhibitor or the cancer has acquired resistance to a combination of monotherapy treatment with the kinase inhibitor and chemotherapy. 50. The composition according to any one of items 1 to 49, for the use as defined in any one of items 1 to 49, wherein the cancer expresses wild-type FLT3. 51. The composition according to any one of items 1 to 49, for the use as defined in any one of items 1 to 49, wherein the cancer expresses a mutated FLT3. 52. The composition according to item 51, for the use as defined in item 51, wherein the mutant FLT3 is activated by mutation. 53. The composition according to item 51 or 52, for the use as defined in any one of items 51 or 52, wherein the mutated FLT3 is mutated in the tyrosine kinase domain. 54. The composition according to any one of items 51 to 53, for the use as defined in any one of items 51 to 53, wherein the mutated FLT3 comprises an internal tandem duplication. 55. The composition according to any one of items 1 to 54, for the use as defined in any one of items 1 to 54, wherein the treatment is a first-line therapy. 56. The composition according to any one of items 1 to 54, for the use as defined in any one of items 1 to 54, wherein the treatment is second line therapy, third line therapy, or fourth line therapy. 57. A chimeric antigen receptor capable of binding to FLT3. 58. The chimeric antigen receptor according to item 57, comprising an IgG4-Fc hinge spacer, a CD28 transmembrane and costimulatory domain, and a CD3z signaling domain. 59. The chimeric antigen receptor according to any one of items 57 or 58, comprising a sequence as set forth in SEQ ID NO: 2 or a sequence that is at least 90% identical to that sequence, or comprising a sequence as set forth in SEQ ID NO: 4 or a sequence that is at least 90% identical to that sequence. 60. The chimeric antigen receptor according to item 59, comprising the sequence of SEQ ID NO: 2 or a sequence which is at least 90% identical to that sequence. 61. The chimeric antigen receptor according to item 59, comprising the sequence of SEQ ID NO: 4 or a sequence which is at least 90% identical to that sequence. 62. The chimeric antigen receptor according to any one of items 57 or 58, comprising a heavy chain variable domain sequence of SEQ ID NO: 5 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 6 or a sequence that is at least 90% identical to that sequence, or comprising a heavy chain variable domain sequence of SEQ ID NO: 7 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 8 or a sequence that is at least 90% identical to that sequence. 63. The chimeric antigen receptor according to item 62, comprising a heavy chain variable domain sequence of SEQ ID NO: 5 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 6 or a sequence that is at least 90% identical to that sequence. 64. The chimeric antigen receptor according to item 62, comprising a heavy chain variable domain sequence of SEQ ID NO: 7 or a sequence that is at least 90% identical to that sequence and a light chain variable domain sequence of SEQ ID NO: 8 or a sequence that is at least 90% identical to that sequence. 65. A cell comprising a chimeric antigen receptor according to any one of items 57 to 64. 66. The cell according to item 65, wherein the cell expressing the chimeric antigen receptor is obtainable by expressing the chimeric antigen receptor through stable gene transfer. 67. The cell according to item 65, wherein the cell expressing the chimeric antigen receptor is obtainable by expressing the chimeric antigen receptor through transient gene transfer. 68. The cell according to any one of items 65 to 67, which is a cell selected from the group of T cells, NK cells, and B cells. 69. The cell according to item 68, which is a T cell. 70. The cell according to any one of items 65 to 69, which is CD8 positive. 71. The cell according to any one of items 65 to 70, which is CD4 positive. 72. An FLT3 targeted agent for use in a method of treating cancer. 73. The FLT3 targeting agent according to item 72, for the use as defined in item 72, wherein the method for treating cancer is a method for treating cancer using a kinase inhibitor. 74. The FLT3 targeting agent according to any one of items 72 or 73, for the use as defined in any one of items 72 or 73, wherein the FLT3 targeting agent is an FLT3 targeting agent as defined in any one of items 3 to 20. 75. The FLT3 targeting agent according to any one of items 72 to 74, for the use as defined in any one of items 72 to 74, wherein the kinase inhibitor is a kinase inhibitor as defined in any one of items 21 to 38. 76. The FLT3 targeting agent according to any one of items 72 to 75, for the use as defined in any one of items 72 to 75, wherein the cancer is a cancer as defined in any one of items 43 to 54. 77. The FLT3 targeting agent according to any one of items 72 to 76, for the use as defined in any one of items 72 to 76, wherein the use is a use as defined in any one of items 1 to 56. 78. The FLT3 targeting agent according to any one of items 72 to 77, for the use as defined in any one of items 72 to 77, wherein the kinase inhibitor is administered at least once or more prior to, simultaneously with, or after administration of the FLT3 targeting agent. 79. The FLT3 targeting agent according to item 78, for the use as defined in item 78, wherein the kinase inhibitor is administered at least once or more times prior to administration of the FLT3 targeting agent. 80. The FLT3 targeting agent according to item 78, for the use as defined in item 78, wherein the kinase inhibitor is administered at least once or more simultaneously with the administration of the FLT3 targeting agent. 81. The FLT3 targeting agent according to item 78, for the use as defined in item 78, wherein the kinase inhibitor is administered at least once or more times after administration of the FLT3 targeting agent. 82. A kit comprising an FLT3 targeting agent and a kinase inhibitor. 83. The kit according to item 82, wherein the FLT3 targeting agent is an FLT3 targeting agent as defined in any one of items 3 to 20. 84. The kit according to any one of items 82 or 83, wherein the kinase inhibitor is a kinase inhibitor as defined in any one of items 21 to 38. 85. The kit of any one of items 82 to 84, wherein the FLT3 targeting agent further comprises a pharma- ceutically acceptable carrier. 86. The kit according to any one of items 82 to 85, wherein the kinase inhibitor further comprises a pharma- ceutically acceptable carrier. 87. (a) a kinase inhibitor, and (b) FLT3 targeting drug A composition comprising: 88. The composition according to item 87, wherein the FLT3 targeting agent is an FLT3 targeting agent as defined in any one of items 3 to 20. 89. The composition according to any one of items 87 or 88, wherein the kinase inhibitor is a kinase inhibitor as defined in any one of items 21 to 38. 90. The composition according to any one of items 87 to 89, further comprising a pharma- ceutically acceptable carrier. 91. The composition according to any one of items 87 to 90, wherein the composition is suitable for the treatment of cancer. 92. The composition according to item 91, wherein the cancer is a cancer as defined in any one of items 43 to 54. 93. A combination of an FLT3 targeting agent and a kinase inhibitor according to item 72. 94. The combination according to item 93 for use in a method for treating cancer in a patient. 95. The combination according to item 93 or the combination for use as defined in item 94, wherein the FLT3 targeting agent is a FLT3 targeting agent as defined in any one of items 3 to 20. 96. The combination according to item 93 or the combination for use as defined in any one of items 94 to 95, wherein the kinase inhibitor is a kinase inhibitor as defined in any one of items 21 to 38. 97. The combination according to item 93 or the combination for use as defined in any one of items 94 to 96, wherein the cancer is a cancer as defined in any one of items 43 to 54. 98. The combination according to item 93, wherein the use is a use as defined in any one of items 1 to 56 or a combination for use as defined in any one of items 94 to 97. 99. A combination of FLT3 CAR-T cells and a kinase inhibitor for use in a method for treating cancer, the combination being administered prior to or following allogeneic hematopoietic stem cell transplantation to treat the cancer. 100. The combination for use as defined in item 99, wherein the FLT3 CAR-T cells are autologous FLT3 CAR-T cells. 101. The combination for use as defined in item 99, wherein the FLT3 CAR-T cells are allogeneic FLT3 CAR-T cells. 102. A combination for use as defined in any one of items 99 to 101, wherein the cancer is a cancer as defined in any one of items 43 to 54. 103.Cancer, FLT3-ITD + 103. The combination for use as defined in any one of items 99 to 102, which is AML. 104. A combination for use as defined in any one of items 99 to 103, wherein the kinase inhibitor is as defined in any one of items 21 to 38. 105. The combination for use as defined in any one of items 99 to 104, wherein the kinase inhibitor is crenolanib.

[0013] In a preferred embodiment, a chimeric antigen receptor according to the invention comprises a costimulatory domain capable of mediating costimulation on immune cells.

[0014] Preferably, the costimulatory domain is derived from 4-1BB, CD28, Ox40, ICOS or DAP10.

[0015] The chimeric antigen receptor according to the invention further comprises a transmembrane domain, preferably a transmembrane domain derived from CD4, CD8 or CD28.

[0016] The chimeric antigen receptor according to the invention preferably further comprises a CAR spacer domain, said CAR spacer domain preferably being derived from CD4, CD8, an Fc-receptor, an immunoglobulin or an antibody. [Brief description of the drawings]

[0017] [Figure 1] Figure 3 shows the FLT3 CAR construct. Construction of FLT3 CAR, CD19 CAR and CD123 CAR used in the study. Single chain variable fragment (scFv) antigen binding domains were derived from mAbs 4G8 and BV10 (FLT3 CAR), FMC63 (CD19 CAR) and 32716 (CD123 CAR). The scFv domains were linked to the intracellular domain via an IgG4 hinge spacer and a CD28 transmembrane domain. CD28 and CD3z were incorporated as co-stimulatory and signaling domains, respectively. A truncated epidermal growth factor receptor (tEGFR), separated from the CAR transgene by a T2A ribosomal skip sequence, was incorporated for detection and enrichment of CAR-positive cells. [Diagram 2]Phenotype of FLT3 CAR-T cells. T cells isolated from peripheral blood mononuclear cells of healthy donors or AML patients were stimulated with CD3 / CD28 beads, lentivirally transduced with the CAR transgene, stained with biotinylated anti-tEGFR antibody followed by anti-biotin magnetic bead staining (8-10 days later), and sorted using magnetic activated cell sorting (MACS). Flow cytometric analysis of CAR expression by CD8+ and CD4+ T cells after MACS sorting. [Diagram 3] Graphs showing that FLT3 CAR-T cells specifically recognize FLT3-transduced K562 tumor cells. K562 / FLT3 was generated by retroviral transduction with the full-length human FLT3 gene. (a) Flow cytometric analysis of FLT3 expression by K562 native and K562 / FLT3 cells. (b) Specific cytolytic activity of CD8+FLT3 CAR-T cells analyzed after 4 hours in a bioluminescence-based cytotoxicity assay. Values ​​are shown as mean + sd. The graph on the right shows the cytolytic activity of CAR T cells prepared from three different T cell donors. [Figure 4]Figure 2 shows that FLT3 CAR-T cells recognize and eliminate FLT3 wild-type and FLT3-ITD+ AML cell lines and primary AML cells in vitro. (a) Flow cytometry analysis of FLT3 expression in AML cell lines (MOLM-13, THP-1, MV4;11) and primary AML blasts (pt#1 and #2). Histograms show staining with anti-FLT3 mAb (4G8) (solid line) and isotype control antibody (striped line). ΔMFI (difference in mean fluorescence intensity) values ​​represent the MFI of cells stained with anti-FLT3 mAb and isotype control. (b) Specific cytolytic activity of CD8+FLT3 CAR-T cells, CD19 CAR-T cells, or untransduced T cells (UTD) against AML cell lines analyzed after 4 hours in a bioluminescence-based cytotoxicity assay. Assays were performed in triplicate wells with 5,000 target cells per well at the indicated effector to target cell ratios. Values ​​are shown as mean + sd. (c) Specific cytolytic activity of CD8+FLT3 and CD8+CD123 CAR-T cells against primary AML blasts analyzed in a 4-hour flow cytometry-based cytotoxicity assay. Assays were performed in triplicate wells with 10,000 target cells per well at the indicated effector to target cell ratios. Bead counting was used to quantify the number of viable primary AML blasts remaining at the end of co-culture and specific lysis was calculated. [Diagram 5]Graphs showing that FLT3 CAR-T cells produce effector cytokines and proliferate after stimulation with MOLM-13 AML cells. (a) Enzyme-linked immunosorbent assay (ELISA) for detection of IFN-γ and IL-2 in supernatants from 24-h coculture of CD4+ and CD8+ FLT3 CAR-T cells with MOLM-13 target cells at an E:T ratio of 2:1. Values ​​are shown as mean ± sd. (b) Proliferation of FLT3 CAR-T cells examined by carboxyfluorescein succinimidyl ester (CFSE) dye dilution after 72-h coculture with MOLM-13 target cells at an E:T ratio of 2:1. Histograms show proliferation of viable (7-AAD-) CD4+ or CD8+ T cells. No exogenous cytokines were added to the assay medium. Data shown are representative of results from FLT3 CAR-modified and control T cell lines prepared from at least n=5 donors. [Figure 6] Graphs showing that FLT3 CAR-T cells produce effector cytokines and proliferate after stimulation with THP-1 AML cells. (a) Enzyme-linked immunosorbent assay (ELISA) for detection of IFN-γ and IL-2 in supernatants from 24-h coculture of CD4+ and CD8+ FLT3 CAR-T cells with MOLM-13 target cells at an E:T ratio of 2:1. Values ​​are shown as mean ± sd. (b) Proliferation of FLT3 CAR-T cells examined by carboxyfluorescein succinimidyl ester (CFSE) dye dilution after 72-h coculture with MOLM-13 target cells at an E:T ratio of 2:1. Histograms show proliferation of viable (7-AAD-) CD4+ or CD8+ T cells. No exogenous cytokines were added to the assay medium. Data shown are representative of results from FLT3 CAR-modified and control T cell lines prepared from at least n=5 donors. [Figure 7]Figure 1 shows that FLT3 CAR-T cells confer potent anti-leukemic activity in vivo in a xenograft model of AML in immunocompromised mice. 6-8 week old female NSG mice were inoculated with 1x106 MOLM-13 AML cells [firefly luciferase (ffluc)+ / green fluorescent protein (GFP)+] and treated with 5x106 CAR modified T cells or UTD T cells on day 7 or left untreated. (a) Stepwise bioluminescence imaging (BLI) to assess leukemic progression and regression in each treatment group. Note that the scale (right) indicates the upper and lower BL thresholds at each analysis time point. (b) Flow cytometry analysis of peripheral blood on day 1 after T cell transfer (i.e., day 10 after leukemic inoculation). Data show the frequency of transferred T cells (CD45+ / CD3+) as a percentage of viable (7-AAD-) cells in each of the treatment groups. [Figure 8] Graphs showing that FLT3 CAR-T cells confer potent anti-leukemic activity in vivo in a xenograft model of AML in immunocompromised mice. (a) Flow cytometry analysis of peripheral blood (PB), spleen (Sp) and bone marrow (BM) at the experimental endpoint in each mouse. Dot plots show the frequency of leukemic cells (GFP+ / FLT3+) as a percentage of viable (7-AAD-) cells in one representative mouse per group. Diagram shows the frequency of leukemic cells (GFP+ / FLT3+) as a percentage of viable (7-AAD-) cells. p<.05 (Student's t-test). (b) Waterfall plots showing the Δ(increase / decrease) of absolute bioluminescence values ​​obtained from each mouse between days 7 and 14 of the experiment [i.e. (day 14 post-tumor inoculation)-(day 7 post-tumor inoculation) i.e. (day 7 post-T cell transfer)-(before T cell transfer)]. Bioluminescence values ​​were obtained as photons / sec / cm2 / sr in a region of interest encompassing the entire body of each mouse. [Figure 9]Graphs showing that FLT3 CAR-T cells show long-term persistence after adoptive transfer, resulting in improved survival of NSG / MOLM-13 mice. (a) Flow cytometry dot plots from bone marrow, spleen, and peripheral blood of a representative mouse from each treatment group. The figures on the right represent the percentage of CD8+ T cells in mice treated with UTD or FLT3 CAR T cells. Values ​​are shown as mean ± sd. (b) Kaplan-Meier analysis of survival in each of the treatment groups. As per the protocol, experimental endpoints were defined by relative (%) loss of body weight and total bioluminescence values. p<.05 (log-rank test). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=3 donors. [Figure 10] Midostaurin treatment leads to enhanced FLT3 expression in AML cells. (a) Flow cytometric analysis of FLT3 expression in MOLM-13, MV4;11, THP-1, and K562 cells cultured in the presence of midostaurin at 10 nM for 15 days followed by stepwise increases to 50 nM concentrations by the end of 3 months. Histograms show staining with anti-FLT3 mAb (4G8) (grey histograms) compared to the isotype (black histograms). ΔMFI (difference in mean fluorescence intensity) values ​​represent the absolute difference between the MFI of untreated cells and the MFI of cells treated with 50 nM midostaurin [i.e. (MFI of 50 nM midostaurin treatment) - (MFI of untreated)]. (b) Flow histograms show FLT3 expression in MOLM-13 cells cultured in the presence of midostaurin at 10 nM for 2-3 weeks, then increased in concentration to 50 nM for the next 8-10 weeks. (c) Flow histograms show FLT3 expression in MOLM-13 cells after exposure to 50 nM midostaurin (Exposure), followed by 2 days after drug cessation (Stop), and 7 days after re-exposure to 50 nM crenolanib (Re-Exposure). [Figure 11]Graphs showing that MOLM-13mido showed lower CD33 and CD123 expression in vitro. (a) Flow cytometry analysis of CD33 and CD123 expression in MOLM-13native (dark grey) and MOLM-13mido (light grey) cells. Representative data from n=2 independent experiments. [Figure 12] Graphs showing that FLT3 CAR-T cells exert enhanced cytotoxicity against MOLM-13mido in vitro. (a) Recognition of MOLM-13mido and MOLM-13native AML cells by FLT3 CAR-T cells. Assays with MOLM-13mido were performed in medium containing 50 nM midostaurin. Cytolytic activity in a bioluminescence-based cytotoxicity assay (5,000 target cells per well, E:T ratio 10:1, 4 hour incubation). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. **p<.005, ***p<.0005 (Student's t-test). [Figure 13] Graphs showing that FLT3 CAR-T cells exhibit enhanced cytokine production and proliferation in vitro versus MOLM-13mido. (a) IFN-γ ELISA and IL-2 ELISA (50,000 T cells per well, 4:1 E:T ratio, 24 h incubation). (b) CD4+FLT3 CAR-T cell proliferation assessed by CFSE dye dilution (50,000 T cells per well co-cultured with 12,500 target cells for 72 h). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. ****p<.0001 (Student's t-test). [Figure 14]Graph showing that Crenolanib treatment leads to enhanced FLT3 expression in AML cells. (a) Flow cytometry analysis of FLT3 expression in MOLM-13, MV4;11, THP-1, and K562 cells cultured for 7 days in the presence of 10 nM Crenolanib compared to untreated cells. Histograms show staining with anti-FLT3 mAb (4G8) (grey histograms) compared to isotype (black histograms). ΔMFI (difference in mean fluorescence intensity) values ​​represent the absolute difference between the MFI of untreated cells and the MFI of cells treated with 10 nM Crenolanib [i.e., (MFI of 10 nM Crenolanib treatment) - (MFI of untreated)]. (b) Flow histograms show FLT3 expression in MOLM-13 cells 7 days after exposure to 10 nM crenolanib (Exposure), followed by 2 days after drug cessation (Stop), and 7 days after re-exposure to 10 nM crenolanib (Re-Exposure). [Figure 15] Graph showing that Crenolanib treatment leads to enhanced FLT3 expression in MOLM-13. On day 0, 1×106 efluro 670 dye-labeled MOLM-13 cells were plated in 48-well plates in 1 mL of culture medium with or without 10 nM Crenolanib (in triplicate wells). (a) After 5 and 10 days, cells were washed and stained for FLT3 expression using anti-FLT3 mAb. Growth was tracked using efluro 647 dye labeling. Solid line indicates untreated MOLM-13 cells (0 nM) and striped line indicates 10 nM Crenolanib-treated MOLM-13 cells. Representative data from n=2 independent experiments. (b) Percentage of MOLM-13 dead cells (7-AAD+ cells) after 0 nM Crenolanib treatment and after 10 nM Crenolanib treatment. Black arrows indicate medium replacement with fresh drug supplementation. Data represent mean + sd from n = 2 independent experiments. [Figure 16]Graphs showing that CD33 and CD123 expression are not altered in MOLM-13creno. (a) Flow cytometry analysis of CD33 and CD123 expression in MOLM-13native (dark grey) and MOLM-13creno cells (light grey). Representative data from n=2 independent experiments. [Figure 17] Graph showing that FLT3 CAR-T cells exert enhanced cytotoxicity against MOLM-13creno in vitro. (a) Recognition of MOLM-13creno and MOLM-13nativeAML cells by FLT3 CAR-T cells. Assays with MOLM-13creno were performed in medium containing 10 nM crenolanib. Cytolytic activity in a bioluminescence-based cytotoxicity assay (5,000 target cells per well, E:T ratio 10:1, 4 hour incubation). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. *p<.05, **p<.005 (Student's t-test). [Figure 18] Graphs showing that FLT3 CAR-T cells exhibit enhanced cytokine production and proliferation in vitro versus MOLM-13creno. (a) IFN-γ ELISA and IL-2 ELISA (50,000 T cells per well, 4:1 E:T ratio, 24 h incubation). (b) CD4+FLT3 CAR-T cell proliferation was assessed by CFSE dye dilution (50,000 T cells per well co-cultured with 12,500 target cells for 72 h). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. *p<.05, ***p<.0005 (Student's t-test). [Figure 19]Graph showing that Quizartinib treatment leads to enhanced FLT3 expression in AML cells. (a) Flow cytometry analysis of FLT3 expression in MOLM-13, MV4;11, THP-1, and K562 cells cultured in the presence of 1 nM Quizartinib for 7 days compared to untreated cells. Histograms show staining with anti-FLT3 mAb (4G8) (grey histogram) compared to isotype (black histogram). ΔMFI (difference in mean fluorescence intensity) values ​​represent the absolute difference between the MFI of untreated cells and the MFI of cells treated with 1 nM Quizartinib [i.e. (MFI of 1 nM Quizartinib treatment) - (MFI of untreated)]. (b) Flow histograms show FLT3 expression in MOLM-13 cells after 7 days of exposure to 1 nM quizartinib (Exposure), followed by 2 days after drug cessation (Stop), and 7 days after re-exposure to 1 nM quizartinib (Re-Exposure). [Figure 20] Graphs showing that CD33 and CD123 expression are not altered in MOLM-13quiza. (a) Flow cytometry analysis of CD33 and CD123 expression in MOLM-13native (dark grey) and MOLM-13quiza (light grey) cells. Representative data from n=2 independent experiments. [Figure 21] Graph showing that FLT3 CAR-T cells exhibit enhanced cytotoxicity against MOLM-13quiza in vitro. (a) Recognition of MOLM-13quiza AML cells and MOLM-13native AML cells by FLT3 CAR-T cells. Assays with MOLM-13quiza were performed in medium containing 1 nM quizartinib. Cytolytic activity in a bioluminescence-based cytotoxicity assay (5,000 target cells per well, E:T ratio 10:1, 4 hour incubation). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. *p<.05, **p<.005 (Student's t-test). [Figure 22]Graphs showing enhanced cytokine production and proliferation of FLT3 CAR-T cells in vitro versus MOLM-13quiza. (a) IFN-γ ELISA and IL-2 ELISA (50,000 T cells per well, 4:1 E:T ratio, 24 h incubation). (b) Proliferation of CD4+FLT3 CAR-T cells was assessed by CFSE dye dilution (50,000 T cells per well co-cultured with 12,500 target cells for 72 h). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. **p<.005, ***p<.0005 (Student's t-test). [Figure 23] Figure 1: Crenolanib acts synergistically with FLT3 CAR-T cells to enhance the anti-leukemia efficacy of FLT3 CAR-T cells in vivo. 6-8 week old female NSG mice were inoculated with 1x106 MOLM-13 cells (ffluc+GFP+) and treated on day 7 with 5x106 FLT3 CAR T cells alone, Crenolanib alone (15mg per kg body weight, ip injection), or both, or left untreated. The first dose of Crenolanib was given on day 7, and mice received 15 doses over three consecutive weeks (Monday-Friday). (a) Stepwise bioluminescence imaging to assess leukemia progression and regression in each treatment group. Note that the scale (right) indicates the upper and lower BL thresholds at each analysis time point. (b) Percentage of viable (7-AAD-) T cells (CD45+CD3+) in peripheral blood of mice receiving FLT3 CAR T cells alone or Crenolanib plus FLT3 CAR T cells (4 days after T cell injection, i.e., after 5 doses of Crenolanib) (top panel). Mice from the untreated and Crenolanib only treated groups were analyzed for FLT3 expression in viable (7-AAD-) leukemia cells (GFP+CD45+) derived from bone marrow (after 5 doses of Crenolanib) (bottom panel). Data were analyzed using Student's t-test (*p<.05, **p<.005). [Figure 24]Graphs showing that crenolanib acts synergistically with FLT3 CAR-T cells to enhance the anti-leukemia efficacy of FLT3 CAR-T cells in vivo. (a) Waterfall plot showing the difference in absolute bioluminescence values ​​obtained from each mouse between days 7 and 14 after tumor inoculation [i.e. (day 14 after tumor inoculation)-(day 7 after tumor inoculation) i.e. (day 7 after T cell transfer)-(before T cell transfer)]. Bioluminescence values ​​were obtained as photons / sec / cm2 / sr in a region of interest encompassing the entire body of each mouse. (b) Kaplan-Meier analysis of survival in each of the treatment groups. As per protocol, the experimental endpoints were defined by the relative (%) reduction in body weight and total bioluminescence values. *p<.05 (log-rank test). [Diagram 25] Graphs showing that combination treatment with Crenolanib and FLT3 CAR-T cells leads to significantly enhanced survival of NSG / MOLM-13 mice compared to monotherapy. (a) Expression of FLT3 was analyzed in MOLM-13 cells obtained from peripheral blood of mice treated or not with Crenolanib. *p<.05 (Student's t-test). (b) Diagram shows the frequency of leukemic cells (GFP+ / CD45+) obtained from bone marrow, spleen and peripheral blood as a percentage of viable (7-AAD-) cells. *p<.05, **p<.005 (Student's t-test). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. [Figure 26] Graph showing phenotype of CAR T cells after EGFRt enrichment. T cells isolated from peripheral blood mononuclear cells of healthy donors or AML patients were stimulated with CD3 / CD28 beads, lentivirally transduced with the CAR transgene, stained with biotinylated anti-tEGFR antibody (after 8-10 days), and then sorted using anti-biotin magnetic bead staining and magnetic activated cell sorting (MACS). Flow cytometry analysis of CAR expression by CD8+ and CD4+ T cells after MACS sorting. [Figure 27]Graphs showing that FLT3 CAR-T cells specifically recognize FLT3+K562 tumor cells. K562 / FLT3 was generated by retroviral transduction with the full-length human FLT3 gene. (a) Flow cytometric analysis of FLT3 expression by K562 native and K562 / FLT3 cells. (b) Specific cytolytic activity of CD8+FLT3 CAR-T cells analyzed after 4 hours in a bioluminescence-based cytotoxicity assay. Values ​​are shown as mean + sd. The graph on the right shows the cytolytic activity of CAR T cells prepared from three different T cell donors. [Figure 28] Graphs showing that FLT3 CAR-T cells recognize and eliminate FLT3 wild-type and FLT3-ITD+ AML cell lines and primary AML cells in vitro. (a) Flow cytometry analysis of FLT3 expression in AML cell lines (MOLM-13, THP-1, MV4;11) and primary AML blasts (pt#1 and #2). Histograms show staining with anti-FLT3 mAb (4G8) (solid line) and isotype control antibody (striped line). ΔMFI (difference in mean fluorescence intensity) values ​​represent the MFI of cells stained with anti-FLT3 mAb and isotype control. (b) Specific cytolytic activity of CD8+FLT3 CAR-T cells, CD19 CAR-T cells, or untransduced T cells (UTD) against AML cell lines analyzed after 4 hours in a bioluminescence-based cytotoxicity assay. Assays were performed in triplicate wells with 5,000 target cells per well at the indicated effector to target cell ratios. Values ​​are shown as mean + sd. (c) Specific cytolytic activity of CD8+FLT3 and CD8+CD123 CAR-T cells against primary AML blasts analyzed in a 4-hour flow cytometry-based cytotoxicity assay. Assays were performed in triplicate wells with 10,000 target cells per well at the indicated effector to target cell ratios. Bead counting was used to quantify the number of viable primary AML blasts remaining at the end of co-culture and specific lysis was calculated. [Figure 29] Graphs showing that FLT3 CAR-T cells produce effector cytokines and proliferate against MOLM-13 AML cells. (a) Enzyme-linked immunosorbent assay (ELISA) to detect IFN-γ and IL-2 in supernatants from 24-h coculture of CD4+ and CD8+ FLT3 CAR-T cells with MOLM-13 target cells at an E:T ratio of 2:1. Values ​​are shown as mean ± sd. (b) Proliferation of FLT3 CAR-T cells examined by carboxyfluorescein succinimidyl ester (CFSE) dye dilution after 72-h coculture with MOLM-13 target cells at an E:T ratio of 2:1. Histograms show proliferation of viable (7-AAD-) CD4+ or CD8+ T cells. No exogenous cytokines were added to the assay medium. Data shown are representative of results from FLT3 CAR-modified and control T cell lines prepared from at least n=5 donors. [Diagram 30] Graphs showing that FLT3 CAR-T cells produce effector cytokines and proliferate against THP-1 AML cells. (a) Enzyme-linked immunosorbent assay (ELISA) for detection of IFN-γ and IL-2 in supernatants from 24-h coculture of CD4+ and CD8+ FLT3 CAR-T cells with MOLM-13 target cells at an E:T ratio of 2:1. Values ​​are shown as mean ± sd. (b) Proliferation of FLT3 CAR-T cells examined by carboxyfluorescein succinimidyl ester (CFSE) dye dilution after 72-h coculture with MOLM-13 target cells at an E:T ratio of 2:1. Histograms show proliferation of viable (7-AAD-) CD4+ or CD8+ T cells. No exogenous cytokines were added to the assay medium. Data shown are representative of results from FLT3 CAR-modified and control T cell lines prepared from at least n=5 donors. [Diagram 31]Figure 1 shows that FLT3 CAR-T cells confer potent anti-leukemic activity in vivo in a xenograft model of AML in immunocompromised mice. 6-8 week old female NSG mice were inoculated with 1x106 MOLM-13 AML cells [firefly luciferase (ffluc)+ / green fluorescent protein (GFP)+] and treated with 5x106 CAR modified T cells or UTD T cells on day 7 or left untreated. (a) Stepwise bioluminescence imaging (BLI) to assess leukemic progression and regression in each treatment group. Note that the scale (right) indicates the upper and lower BL thresholds at each analysis time point. (b) Flow cytometry analysis of peripheral blood on day 1 after T cell transfer (i.e., day 10 after leukemic inoculation). Data show the frequency of transferred T cells (CD45+ / CD3+) as a percentage of viable (7-AAD-) cells in each of the treatment groups. [Diagram 32] Graphs showing that FLT3 CAR-T cells reduce leukemic burden and improve survival in vivo in a xenograft model of AML in immunocompromised mice. (a) Waterfall plot showing the delta (increase / decrease) of absolute bioluminescence values ​​obtained from each mouse between days 7 and 14 of the experiment [i.e. (day 14 post-tumor inoculation)-(day 7 post-tumor inoculation)-(day 7 post-T cell transfer)-(before T cell transfer)]. Bioluminescence values ​​were obtained as photons / sec / cm2 / sr in a region of interest encompassing the entire body of each mouse. (b) Kaplan-Meier analysis of survival in each of the treatment groups. As per protocol, the experimental endpoints were defined by the relative (%) decrease in body weight and total bioluminescence values. p<.05 (log-rank test). Data shown are representative of results from independent experiments using FLT3 CAR-T cell lines prepared from n=3 donors. [Diagram 33] Graphs showing that FLT3 CAR-T cells eliminate AML from bone marrow, spleen, and peripheral blood in vivo. (a) Flow cytometry analysis from bone marrow, spleen, and peripheral blood of representative mice from each treatment group. Values ​​are shown as mean ± sd. [Diagram 34]Graphs showing that FLT3 CAR-T cells exert enhanced cytotoxicity against MOLM-13mido in vitro. (a) Recognition of MOLM-13mido and MOLM-13native AML cells by FLT3 CAR-T cells. Assays with MOLM-13mido were performed in medium containing 50 nM midostaurin. Cytolytic activity in a bioluminescence-based cytotoxicity assay (5,000 target cells per well, 4-hour incubation at different E:T ratios). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. *p<.05, **p<.005 (Student's t-test). [Diagram 35] Graphs showing that FLT3 CAR-T cells exhibit enhanced cytokine production and proliferation in vitro versus MOLM-13mido. (a) IFN-γ ELISA and IL-2 ELISA (50,000 T cells per well, 4:1 E:T ratio, 24 h incubation). (b) CD4+FLT3 CAR-T cell proliferation was assessed by CFSE dye dilution (50,000 T cells per well co-cultured with 12,500 target cells for 72 h). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. ***p<.0005 (Student's t-test). [Diagram 36]Graphs showing that FLT3 CAR-T cells exert enhanced cytotoxicity against MOLM-13creno in vitro. (a) Recognition of MOLM-13creno and MOLM-13native AML cells by FLT3 CAR-T cells. Assays with MOLM-13creno were performed in medium containing 10 nM midostaurin. Cytolytic activity in a bioluminescence-based cytotoxicity assay (5,000 target cells per well, E:T ratio 10:1, 4-hour incubation). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. *p<.05, **p<.005 (Student's t-test). [Figure 37] Graphs showing that FLT3 CAR-T cells exhibit enhanced cytokine production and proliferation in vitro versus MOLM-13creno. (a) IFN-γ ELISA and IL-2 ELISA (50,000 T cells per well, 4:1 E:T ratio, 24 h incubation). (b) CD4+FLT3 CAR-T cell proliferation assessed by CFSE dye dilution (50,000 T cells per well co-cultured with 12,500 target cells for 72 h). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. *p<.05, **p<.005 (Student's t-test). [Figure 38]Graphs showing that FLT3 CAR-T cells exert enhanced cytotoxicity against MOLM-13quiza in vitro. (a) Recognition of MOLM-13quiza AML cells and MOLM-13native AML cells by FLT3 CAR-T cells. Assays with MOLM-13quiza were performed in medium containing 1 nM midostaurin. Cytolytic activity in a bioluminescence-based cytotoxicity assay (5,000 target cells per well, E:T ratio 10:1, 4-hour incubation). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. *p<.05, **p<.005 (Student's t-test). [Figure 39] Graphs showing that FLT3 CAR-T cells exhibit enhanced cytokine production and proliferation in vitro against MOLM-13quiza. (a) IFN-γ ELISA and IL-2 ELISA (50,000 T cells per well, 4:1 E:T ratio, 24 h incubation). (b) CD4+FLT3 CAR-T cell proliferation was assessed by CFSE dye dilution (50,000 T cells per well co-cultured with 12,500 target cells for 72 h). Data shown are representative of results from independent experiments with FLT3 CAR-T cell lines prepared from n=2 donors. **p<.005, ***p<.0005 (Student's t-test). [Diagram 40]FIG. 1 shows that midostaurin acts synergistically with FLT3 CAR-T cells in vivo to enhance the anti-leukemia activity of FLT3 CAR-T cells. 6-8 week old female NSG immunodeficient mice were injected with 1×106 ffluc+GFP+MOLM-13 cells on day 0. On day 7, mice were treated with a single dose of FLT3 CAR-T cells alone (5×106 cells, CD4+:CD8+ ratio=1:1), midostaurin alone (1 mg per kg body weight, ip injection), or both (combination), or left untreated. Mice in the FLT3 CAR+ initial mido group received midostaurin on days 3, 4, and 5, followed by 12 additional doses of midostaurin starting on day 7. Mice in the FLT3 CAR+midostaurin group received their first dose of midostaurin on day 7 (i.e., the same day as T cell injection) and received a total of 15 doses of midostaurin over three consecutive weeks (Monday-Friday). (a) Graded bioluminescence (BL) imaging to assess leukemia progression / regression in each treatment group. Note that the scales (right) indicate the upper and lower BL thresholds at each analysis time point. (b) Waterfall plot representing the fold change in BL values ​​between days 7 and 11 after tumor inoculation. BL values ​​were obtained as photons / sec / cm2 / sr. [Diagram 41] Graphs showing FLT3 CAR-T cell expansion after midostaurin treatment in vivo and FLT3 expression in MOLM-13 cells. (a) Peripheral blood analysis of mice treated with FLT3 CAR-T cells alone or in combination with midostaurin (day 11 after tumor inoculation). The diagram shows the percentage of viable (7-AAD-) T cells (CD45+CD3+) in peripheral blood. *p<0.05, **p<0.005 (Student's t-test). (b) Flow cytometry analysis of FLT3 expression in MOLM-13 cells was performed on cells obtained from bone marrow of untreated and midostaurin-treated mice (after 5 doses of midostaurin). The diagram shows the mean fluorescence intensity (MFI) of FLT3. [Diagram 42]Figure 1 shows that Quizartinib acts synergistically with FLT3 CAR-T cells in vivo to enhance the anti-leukemic activity of FLT3 CAR-T cells. Female NSG immunodeficient mice (6-8 weeks old) were inoculated with 1x106 ffluc+GFP+MOLM-13 cells on day 0. On day 7, mice were treated with a single dose of FLT3 CAR-T cells alone (5x106 cells, CD4+:CD8+ ratio=1:1), Quizartinib alone (1 mg per kg body weight, ip injection), or both (combination), or left untreated. Mice in the FLT3 CAR+Quizartinib group received their first dose of Quizartinib on day 7 (i.e., the same day as the T cell injection), and mice received a total of 15 doses of Quizartinib over three consecutive weeks (Monday-Friday). (a) Stepwise bioluminescence (BL) imaging to assess leukemia progression / regression in each treatment group. (b) Waterfall plot represents the fold change in BL values ​​between days 7 and 10 after tumor inoculation. BL values ​​were obtained as photons / sec / cm2 / sr. [Diagram 43] Graphs showing in vivo FLT3 CAR-T cell expansion after Quizartinib treatment and analysis of FLT3 expression in MOLM-13 cells. (a) Peripheral blood analysis of mice treated with FLT3 CAR-T cells alone or in combination with Quizartinib (day 10 after tumor inoculation). The diagram shows the percentage of viable (7-AAD-) T cells (CD45+CD3+) in peripheral blood. **p<0.005 (Student's t-test). (b) Flow cytometric analysis of FLT3 expression in MOLM-13 cells was performed on cells obtained from bone marrow of untreated mice and mice treated with Quizartinib (after 5 doses of Quizartinib). The diagram shows the mean fluorescence intensity (MFI) of FLT3. [Diagram 44]Graphs showing FLT3 expression in acute lymphoblastic leukemia (ALL) and mixed lineage leukemia (MLL) cell lines in vitro and their recognition by FLT3 CAR-T cells. (a) Flow cytometry analysis of FLT3 expression in ALL (NALM-16) and MLL (KOPN-8 and SEM) cells. Inset numbers represent absolute difference in MFI of anti-FLT3 staining versus MFI of isotype staining. (b) Specific cytolytic activity of FLT3 CAR-T cells versus ALL and MLL cell lines as target cells in a 4-hour cytotoxicity assay. Values ​​show mean ± sd. [Diagram 45] IL-2 production and proliferation mediated by CD4+FLT3 CAR-T cells against ALL and MLL cell lines. (a) IL-2 production by FLT3 CAR-T cells measured by ELISA after 24 h incubation with target cells at an E:T ratio of 2:1 (50,000 T cells per well). (b) Proliferation of FLT3 CAR-T cells and control CD19 CAR-T cells investigated by CFSE dye dilution after 72 h co-culture with target cells. Representative data for T cells prepared from n=2 different donors. [Figure 46] Graph showing FLT3 expression in ALL and MLL cell lines after treatment with FLT3 inhibitors: (a) Flow cytometric analysis of FLT3 expression in ALL and MLL cell lines cultured for 1 week in the absence or presence of 50 nM midostaurin, 10 nM crenolanib, or 1 nM quizartinib. [Figure 47]Graph showing antibody-dependent cellular cytotoxicity (ADCC) against MV4;11 AML cells pretreated with and without FLT3 inhibitors. MV4;11 AML cells were treated with FLT3 inhibitors (10 nM crenolanib, 1 nM quizartinib or 50 nM midostaurin) for 7 days. PBMCs from healthy donors (effector / target ratio 50:1) and control IgG1 antibody or anti-FLT3 BV10 mAb were added at a concentration of 5000 ng / mL. MV4;11 cells were stably expressing firefly luciferase and after 24 h of co-culture, cell viability was analyzed by bioluminescence measurement after addition of luciferin substrate. Values ​​are shown as mean ± SD. P values ​​between the indicated groups were calculated by using unpaired Student's t-test. *P<.05; **P<.005. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present invention generally relates to the treatment of cancer with FLT3-targeting drugs and kinase inhibitors. In particular, the present invention relates to the treatment of acute myeloid leukemia (AML) with T cells genetically modified to express FLT3-specific chimeric antigen receptors (CARs) in combination with FLT3 inhibitors. In this invention, the inventors demonstrate that treatment of AML blast cells with FLT3 inhibitors leads to a significant increase in the expression of FLT3 molecules on the cell surface of AML blast cells, which in turn leads to a significant increase in recognition and elimination by FLT3 CAR-T cells. The combination treatment of AML with FLT3 CAR-T cells and FLT3 inhibitors is highly synergistic and is superior to monotherapy with either FLT3 inhibitors or FLT3 CAR-T cells alone.

[0019] Recent clinical trials have demonstrated that adoptive immunotherapy with CD19 CAR-T cells in B-cell leukemia and lymphoma; and BCMA (B-cell maturation antigen) CAR-T cells in multiple myeloma can be effective against advanced hematological malignancies. However, these clinical trials have also demonstrated that there is a substantial risk of relapse due to the emergence of antigen-deficient tumor variants, as recently demonstrated in the case of CD19 CAR (leukemia relapse due to the emergence of CD19-negative leukemia variants, Ref: Turtle et al J Clin Invest 2016, PMID: 27111235) and BCMA CAR (myeloma relapse due to the emergence of BCMA-negative / low myeloma variants, Ref: Ali et al. Blood 2016, PMID: 27412889). There are several explanations why antigen loss occurs after CAR-T cell therapy, including: i) the CAR target antigen is not uniformly expressed or is not expressed at a high enough level; ii) the CAR target antigen is not pathophysiologically associated with the tumor, and therefore antigen loss may be tolerated by the tumor cells. To date, no methods have been described to prevent the development of antigen-deficient tumor variants under the therapeutic pressure of CAR-T cells. However, the inventors reason that if there were a means to force tumor cells to enhance the expression of CAR target antigens on their cell surface and prevent tumor cells from losing antigens, CAR-T cell therapy would be more effective and a greater percentage of patients would be more likely to be cured of the underlying hematological malignancies. The inventors demonstrate in this invention that it is possible to force AML blasts to enhance the expression of FLT3 molecules by treatment with FLT3 inhibitors. As a result, the recognition and elimination of AML blasts by FLT3 CAR-T cells in vitro and in vivo is significantly enhanced. Treating AML blasts with a FLT3 inhibitor leads to enhanced expression of FLT3 molecules in all AML blasts, thereby increasing the likelihood that all AML blasts will be eliminated by FLT3 CAR-T cells and decreasing the likelihood that AML blasts will escape elimination by FLT3 CAR-T cells.Therefore, combination treatment with FLT3 CAR-T cells and an FLT3 inhibitor is more likely to cure AML than treatment with an FLT3 inhibitor alone or FLT3 CAR-T cells alone.

[0020] FLT3 inhibitors are used to treat AML, but as single agents, they have low clinical efficacy and cannot cure the disease in the vast majority of patients.The results of targeting AML blasts with FLT3 inhibitors on the expression of FLT3 molecules in AML blasts are unpredictable: i) FLT3 expression may be reduced due to the direct toxic effect of FLT3 inhibitors, which disrupts protein synthesis and turnover; ii) FLT3 expression may not change because AML blasts generally acquire new mutations in FLT3 molecules that render FLT3 inhibitors ineffective, or switch to and use alternative molecular survival pathways; iii) FLT3 expression may increase in AML blasts, counteracting the inhibition provided by FLT3 inhibitors.

[0021] The present inventors show that treatment of AML blast cells with FLT3 inhibitors midostaurin, quizartinib and crenolanib leads to a significant increase in FLT3 expression, especially in AML blast cells with FLT3 internal tandem duplication (FLT3-ITD). The increase in FLT3 expression in AML blast cells occurs rapidly after the start of treatment with FLT3 inhibitors, leading to a significant enhancement of recognition by FLT3 CAR-T cells (more potent and rapid cytolytic activity; more potent secretion of cytokines, including IL-2; more potent and rapid proliferation; superior viability and survival after stimulation with AML blast cells). Furthermore, combined treatment of AML with FLT3 CAR-T cells and FLT3 inhibitors leads to a significant enhancement of the persistence and anti-leukemic function of CAR-T cells in vivo in a mouse model of AML. The increase in FLT3 expression in AML blast cells can be modulated and rapidly return to baseline levels when treatment with FLT3 inhibitors is terminated. Surprisingly, FLT3 CAR-T cell viability and function are not affected by midostaurin, quizartinib and crenolanib, even though these agents are each multi-targeted kinase inhibitors and therefore may interfere with FLT3 CAR signaling and function.

[0022] Definitions and embodiments Unless otherwise defined below, terms used in the present invention shall be understood according to their ordinary meanings known to those of ordinary skill in the art.

[0023] Each of the publications, patent applications, patents, and other references cited herein is incorporated by reference in its entirety to the extent not inconsistent with the present invention. The references are identified by their reference number and their corresponding reference details provided in the "References" section.

[0024] A "kinase inhibitor", as referred to herein, is a molecular compound that inhibits one or more kinases by binding to said kinases and exerting an antagonistic effect on said kinases. A kinase inhibitor can bind to one or more kinase species, and upon binding of the kinase inhibitor, the kinase activity of the one or more kinases is reduced. The kinase inhibitors described herein are generally small molecules, which are molecular compounds with low molecular weight (generally less than 1 kDa) and small size (generally less than 1 nM).

[0025] In one embodiment, the kinase inhibitor is a multi-targeted kinase inhibitor. As used herein, a "multi-targeted kinase inhibitor" is a kinase inhibitor that can inhibit more than one type of kinase. In a preferred embodiment, the kinase inhibitor is a tyrosine kinase inhibitor. In another preferred embodiment, the kinase inhibitor is an FLT3 inhibitor. In a more preferred embodiment, the kinase inhibitor inhibits mutant FLT3, more preferably FLT3-ITD. In a more preferred embodiment, the kinase inhibitor is selected from the group consisting of FLT3 kinase inhibitors crenolanib, midostaurin, and quizartinib. In a highly preferred embodiment, the kinase inhibitor is the FLT3 kinase inhibitor crenolanib.

[0026] As used herein, "type II receptor tyrosine kinase inhibitor" targets the inactive conformation of receptor tyrosine kinase, while "type I receptor tyrosine kinase inhibitor" targets the active conformation of receptor tyrosine kinase.Exemplary type II receptor tyrosine kinase inhibitor is FLT3 inhibitor quizartinib.Exemplary type I receptor tyrosine kinase inhibitor is FLT3 inhibitor crenolanib.

[0027] "K D " or "K DThe term "K value" refers to the equilibrium dissociation constant as known in the art. In the context of the present invention, these terms refer to the equilibrium dissociation constant of a targeting agent to a particular antigen of interest (e.g., FLT3). The equilibrium dissociation constant is a measure of the tendency of a complex (e.g., a complex of an antigen and a targeting agent) to reversibly dissociate into its components (e.g., an antigen and a targeting agent). D Methods for determining the value are known in the art.

[0028] A targeted agent as described herein is an agent that is capable of specifically binding to its target, as opposed to a general pharmaceutical agent. The targeting agent according to the present invention is a FLT3 targeting agent. A preferred targeting agent according to the present invention is capable of binding to FLT3 on the cell surface, typically the extracellular domain of the transmembrane protein FLT3.

[0029] In one embodiment of the present invention, the targeting agent can specifically bind to the cells expressing tumor FLT3. In another embodiment of the present invention, the targeting agent can specifically bind to the hematopoietic cells expressing FLT3. In another embodiment of the present invention, the targeting agent can specifically bind to the hematopoietic cells expressing tumor FLT3. In a preferred embodiment of the present invention, the targeting agent can bind to the acute myeloid leukemia cells expressing FLT3. In a highly preferred embodiment of the present invention, the targeting agent can bind to the acute myeloid leukemia cells expressing mutant FLT3, preferably FLT3-ITD.

[0030] "Cell growth inhibition" and like terms, as used herein, refer to an effect that causes a decrease in cell number. This may be caused by cytotoxicity through necrosis or apoptosis, or it may be caused by inhibition or arrest of proliferation, preferably. "Growth inhibitory effect", as used herein, means that a substance, molecule, compound, composition or agent has a growth inhibitory effect on cells compared to the situation in the absence of said substance, molecule, compound, composition or agent. Cell growth inhibition can be measured by various common methods and assays known in the art.

[0031] Whenever the present invention refers to compositions, compositions for use, kits, methods of use, combinations, combinations for use, etc. relating to (a) a kinase inhibitor and (b) an FLT3 targeted agent, it should be understood that the kinase inhibitor is distinct from the FLT3 targeted agent.

[0032] It is further understood that terms such as "kinase inhibitor" refer to the presence of a kinase inhibitor, but do not exclude the possibility that additional kinase inhibitors may be present, e.g., one, two, three or more additional kinase inhibitors. In one embodiment according to the invention, only one kinase inhibitor is used.

[0033] It is also understood that terms such as "FLT3 targeting agent" refer to the presence of a FLT3 targeting agent, but do not exclude the possibility that additional FLT3 targeting agents may be present, e.g., one, two, three or more additional FLT3 targeting agents. In one embodiment according to the invention, only one FLT3 targeting agent is used.

[0034] In one embodiment, the chimeric antigen receptor can bind to FLT3. In a preferred embodiment, the chimeric antigen receptor can bind to the extracellular domain of FLT3. In a preferred embodiment, the chimeric antigen receptor is expressed in immune cells, preferably T cells. In a preferred embodiment of the present invention, the chimeric antigen receptor is expressed in T cells, allowing the T cells to specifically bind to acute myeloid leukemia cells expressing FLT3 with high specificity and exert growth inhibitory effect, preferably cytotoxic effect, on the acute myeloid leukemia cells.

[0035] In a preferred embodiment, the chimeric antigen receptor capable of binding to FLT3 is a chimeric antigen receptor derived from the antigen-binding portion of a monoclonal antibody capable of binding to FLT3, and the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:2 or a sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto.

[0036] In a more preferred embodiment, the chimeric antigen receptor capable of binding to FLT3 is a chimeric antigen receptor, the antigen binding domain of which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:6. In a preferred embodiment, the chimeric antigen receptor capable of binding to FLT3 is a chimeric antigen receptor derived from the antigen-binding portion of a monoclonal antibody capable of binding to FLT3, and the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:4 or a sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto.

[0037] In a more preferred embodiment, the chimeric antigen receptor capable of binding to FLT3 is a chimeric antigen receptor, the antigen binding domain of which comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8.

[0038] "Adoptive immunotherapy" as described herein refers to the transfer of immune cells into a patient for targeted treatment of cancer. The cells can be derived from the patient or from another individual. In adoptive immunotherapy, immune cells, preferably T cells, are generally extracted from an individual, preferably from the patient, genetically modified, cultured in vitro, and administered to the patient. Adoptive immunotherapy is advantageous in that it allows targeted growth inhibitory, preferably cytotoxic, tumor cell therapy without the non-targeted toxicity to non-tumor cells that occurs with conventional therapy.

[0039] In a preferred embodiment according to the invention, T cells are isolated from a patient with acute myeloid leukemia, transduced with a gene transfer vector encoding a chimeric antigen receptor capable of binding FLT3, and administered to the patient to treat acute myeloid leukemia, wherein it is preferred that the acute myeloid leukemia cells express a mutated FLT3, more preferably FLT3-ITD. In a preferred embodiment, the T cells are CD8 + T cells or CD4 + T cells.

[0040] The term antibody, as used herein, refers to any functional antibody capable of specifically binding to an antigen of interest. Without limitation, the term antibody includes antibodies from any appropriate source species, including birds, such as chickens, and mammals, such as mice, goats, non-human primates, and humans. The antibody is preferably a humanized antibody. A humanized antibody is an antibody that contains human sequences and a small portion of non-human sequences that confer binding specificity to an antigen of interest (e.g., human FLT3). The antibody is preferably a monoclonal antibody, which can be prepared by methods well known in the art. The term antibody includes IgG-1, IgG-2, IgG-3, or IgG-4, IgE, IgA, IgM, or IgD isotype antibodies. The term antibody includes monomeric antibodies (e.g., IgD, IgE, IgG, etc.) or oligomeric antibodies (e.g., IgA or IgM, etc.). The term antibody also includes, without limitation, isolated antibodies and genetically engineered antibodies, such as modified antibodies, such as chimeric or bispecific antibodies.

[0041] Antibody fragment or antibody fragment, as used herein, refers to a portion of an antibody that retains the antibody's ability to specifically bind to an antigen (e.g., human FLT3). This ability can be determined, for example, by determining the ability of the antigen-binding portion to compete with the antibody for specific binding to the antigen by methods known in the art. Without particular limitation, antibody fragments can be generated by any suitable method known in the art, including recombinant DNA methods and preparation by chemical or enzymatic fragmentation of antibodies. An antibody fragment can be a Fab fragment, a F(ab') fragment, a F(ab')2 fragment, a single chain antibody (scFv), a single domain antibody, a diabody, or any other portion of an antibody that retains the antibody's ability to specifically bind to an antigen.

[0042] An "antibody" (e.g., a monoclonal antibody) or "fragment thereof" as described herein may be derivatized or linked to a different molecule. For example, molecules that can be linked to antibodies are other proteins (e.g., other antibodies), molecular labels (e.g., fluorescent, luminescent, color-changing, or radioactive molecules), pharmaceuticals, and / or toxic agents. The antibodies or antigen-binding portions can be linked directly (e.g., in the form of a fusion between two proteins) or can be linked via a linker molecule (e.g., any suitable type of chemical linker known in the art).

[0043] The term "internal tandem duplication" (ITD), as used herein in connection with FLT3, refers to a genetic mutation in FLT3 that leads to one or more in-frame trinucleotide duplications (FLT3-ITD) in the juxtamembrane region or other parts of the intracellular domain. This generally results in constitutive activation of FLT3. Internal tandem duplications can range in size from 3 nucleotides to more than 100 nucleotides. FLT3-ITD mutations occur frequently in acute myeloid leukemia and are associated with resistance to conventional therapy and poor clinical outcomes.

[0044] Unless otherwise specified, "monotherapy" as used herein refers to a therapy in which one pharma- ceutical active substance, molecule, compound, composition, or agent is administered as the only pharma- ceutical active substance, molecule, compound, composition, or agent. The term monotherapy, as used herein, does not include the combination of two or more pharma- ceutical active substances, molecules, compounds, compositions, or agents. The term monotherapy also does not include the combination of two or more pharma- ceutical active substances, molecules, compounds, compositions, or agents, where the two or more pharma- ceutical active substances, molecules, compounds, compositions, or agents are not administered simultaneously, but are administered within a treatment regimen.

[0045] Terms such as "treatment of cancer" or "treating cancer" refer to therapeutic treatment according to the present invention. The success of a therapeutic treatment can be evaluated, for example, by evaluating whether the treatment inhibits the growth of the cancer in the treated patient. Preferably, the inhibition is statistically significant as evaluated by appropriate statistical tests known in the art. The inhibition of cancer growth can be evaluated by comparing the growth of the cancer in a group of patients treated according to the present invention with a control group of untreated patients, or by comparing a group of patients receiving standard cancer treatment in the art plus treatment according to the present invention with a control group of patients receiving only standard cancer treatment in the art. Such studies to evaluate the inhibition of cancer growth are designed according to accepted standards for clinical trials, e.g., double-blind, randomized studies with sufficient statistical power. The term "treating cancer" includes inhibition of cancer growth where the cancer growth is partially inhibited (i.e., the growth of the cancer in the patient is delayed compared to a control group of patients), inhibition where the cancer growth is completely inhibited (i.e., the growth of the cancer in the patient is stopped), and inhibition where the cancer growth is reversed (i.e., the cancer shrinks). Successful therapeutic treatment can be assessed based on known clinical indicators of cancer progression.

[0046] It is not excluded that the treatment of cancer according to the present invention also produces an additional or secondary therapeutic benefit in the patient. For example, the additional or secondary benefit may be an enhancement of the engraftment of transplanted hematopoietic stem cells, either before, at the same time as, or after the treatment of the cancer. However, it is understood that the primary treatment for which protection is sought is to treat the cancer itself, and any secondary or additional effect reflects only the additional benefit as required for the treatment of the cancer growth.

[0047] The cancer treatment according to the present invention can be a first line, second line, third line, or fourth line therapy. The treatment can also be a therapy later than a fourth line therapy. The meanings of these terms are known in the art and follow the terminology commonly used by the US National Cancer Institute.

[0048] The term "refractory to induction chemotherapy", as used herein, refers to patients whose disease has not responded to one or two cycles of induction chemotherapy.

[0049] The term "capable of binding" as used herein refers to the ability to form a complex with the molecule to be bound (e.g., FLT3). Binding generally occurs non-covalently through intermolecular forces such as ionic bonds, hydrogen bonds, and van der Waals forces, and is generally reversible. Various methods and assays for determining binding ability are known in the art. Binding is usually high affinity binding, with a K D Affinity, measured in values, is preferably less than 1 μM, more preferably less than 100 nM, even more preferably less than 10 nM, even more preferably less than 1 nM, even more preferably less than 100 pM, even more preferably less than 10 pM, even more preferably less than 1 pM.

[0050] As used herein, each occurrence of the terms "comprising" or "comprises" may be replaced with "consisting of" or "consisting of" where appropriate.

[0051] Pharmaceutically acceptable carriers, including any suitable diluent, as known in the art, can be used in the present invention. As used herein, the term "pharmaceutical acceptable" means approved by a federal or state regulatory agency for use in mammals, more particularly in humans, or listed in the United States Pharmacopoeia, the European Pharmacopoeia, or other generally recognized pharmacopoeias. Pharmaceutically acceptable carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, sterile isotonic aqueous buffer, and combinations thereof. It will be understood that the formulation is appropriately adapted to suit the mode of administration.

[0052] The compositions and formulations according to the present invention are prepared according to known standards for preparing pharmaceutical compositions and formulations. For example, the compositions and formulations are prepared so that they can be appropriately stored and administered by using pharma- ceutically acceptable ingredients, such as carriers, excipients, or stabilizers. Such pharma-ceutically acceptable ingredients are not toxic in the amount used when the pharmaceutical composition or formulation is administered to a patient. The pharma-ceutically acceptable ingredients added to the pharmaceutical composition or formulation may depend on the chemical nature of the inhibitor and targeting agent present in the composition or formulation (depending on whether the targeting agent is, for example, an antibody or a fragment thereof, or a cell expressing a chimeric antigen receptor), the particular intended use of the pharmaceutical composition, and the route of administration.

[0053] In a preferred embodiment according to the invention, the composition or formulation is suitable for administration to humans, and the formulation is preferably sterile and / or non-pyrogenic.

[0054] A preferred embodiment is FLT3-ITD + The combination of FLT3 CAR-T cells and crenolanib to treat AML.

[0055] Another useful embodiment is the combination of FLT3 CAR-T cells with crenolanib to treat FLT3 mutant AML (any mutation other than FLT3-ITD) or FLT3 wild-type AML.

[0056] Another useful embodiment is FLT3-ITD + A combination of FLT3 CAR-T cells with midostaurin, quizartinib, or any other FLT3 inhibitor to treat AML, FLT3 mutated AML, or FLT3 wild-type AML.

[0057] Another useful embodiment is the LT3-ITD + The combination of FLT3 CAR-T cells with one or several FLT3 inhibitors for the treatment of AML, FLT3 mutant AML or FLT3 wild-type AML.

[0058] Another useful embodiment is the LT3-ITD + A combination of FLT3 CAR-T cells with one or several multi-targeted kinase inhibitors for the treatment of AML, FLT3 mutant AML or FLT3 wild-type AML.

[0059] A preferred embodiment is FLT3-ITD + The combination of autologous FLT3 CAR-T cells and crenolanib to treat AML.

[0060] Another useful embodiment is FLT3-ITD + The combination of allogeneic FLT3 CAR-T cells and crenolanib to treat AML.

[0061] In a preferred embodiment, FLT3-ITD + To treat AML, autologous FLT3 CAR-T cells will be administered in combination with crenolanib prior to allogeneic hematopoietic stem cell transplantation.

[0062] In another useful embodiment, the FLT3-ITD + Autologous FLT3 CAR-T cells will be administered in combination with crenolanib after allogeneic hematopoietic stem cell transplantation to treat AML.

[0063] In a useful embodiment, FLT3-ITD +To treat AML, allogeneic FLT3 CAR-T cells will be administered in combination with crenolanib prior to allogeneic hematopoietic stem cell transplantation.

[0064] In another useful embodiment, the FLT3-ITD + Allogeneic FLT3 CAR-T cells will be administered in combination with crenolanib following allogeneic hematopoietic stem cell transplantation to treat AML.

[0065] In a preferred embodiment, FLT3-ITD + To treat AML, CD8+ and CD4 + FLT3 CAR-T cells will be administered in combination with crenolanib.

[0066] In another useful embodiment, the FLT3-ITD + To treat AML, CD8 + Only FLT3 CAR-T cells will be administered in combination with crenolanib.

[0067] In another useful embodiment, the FLT3-ITD + To treat AML, CD4 + Only FLT3 CAR-T cells will be administered in combination with crenolanib.

[0068] In another useful embodiment, the FLT3-ITD + Any other T cells (including but not limited to naive T cells, memory T cells, memory T stem cells, gamma delta T cells, cytokine-induced killer cells, regulatory T cells), NK cells or B cells engineered with the FLT3 CAR are combined with crenolanib to treat AML.

[0069] In a preferred embodiment, the FLT3 CAR is delivered to CD8 + T cells and CD4 + It is expressed in T cells, where stable gene transfer is achieved by viral vectors or non-viral mediated gene transfer.

[0070] In another preferred embodiment, the FLT3 CAR is transfected into CD8 + T cells and CD4 + It is expressed in T cells.

[0071] Another preferred embodiment is FLT3-ITD + Including the combination of FLT3 specific antibodies (including but not limited to monoclonal antibodies, bispecific antibodies, trispecific antibodies, antibody-drug conjugates) with crenolanib to treat AML.

[0072] Another useful embodiment is the combination of FLT3 CAR-T cells with crenolanib to treat acute lymphoblastic leukemia. Another useful embodiment is the combination of FLT3 CAR-T cells with crenolanib to treat mixed lineage leukemia, myelodysplastic syndrome, or any other cancer that expresses FLT3.

[0073] Another useful embodiment is the combination of FLT3 CAR-T cells with crenolanib to eliminate leukemia stem / initiator cells.

[0074] Another useful embodiment is the combination of FLT3 CAR-T cells with crenolanib to eliminate hematopoietic stem cells, hematopoietic progenitor cells, NK cells, and dendritic cells.

[0075] FLT3 targeting agents according to the present invention and their uses The FLT3 targeting agent of the present invention can be any agent capable of specifically binding to its target, where the target is FLT3, preferably a cell expressing FLT3 on its cell surface, and the FLT3 targeting agent facilitates targeted treatment of cell types that express FLT3 without the risk of affecting other cell types. A non-limiting example of a FLT3-targeting agent is a T cell expressing a chimeric antigen receptor (FLT3 CAR-T cell) that can specifically bind to FLT3 and thus target acute myeloid tumor cells that express FLT3.

[0076] Whether a targeting agent is an FLT3 targeting agent can be determined by using the method disclosed herein, which is detailed in the preferred embodiment. The preferred method according to the preferred embodiment is the method used in Examples 1 and 2.

[0077] In one embodiment, the FLT3 targeting agent is a T cell expressing a chimeric antigen receptor capable of binding to FLT3 (FLT3 CAR-T cell).

[0078] In another embodiment, the FLT3 targeted agent is a FLT3 CAR-T cell, and said FLT3 CAR-T cell is administered to a patient in need thereof in a method for treating cancer, preferably for treating leukemia or lymphoma, more preferably for treating leukemia, and most preferably for treating acute myeloid leukemia.

[0079] In a preferred embodiment, the FLT3 targeting agent is a FLT3 CAR-T cell, and said FLT3 CAR-T cell is administered to a patient in need thereof in a method for treating acute myeloid leukemia, wherein the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0080] In a more preferred embodiment, the FLT3 targeting agent is administered to a patient in need thereof in a T cell expressing a chimeric antigen receptor capable of binding to FLT3, said chimeric antigen receptor being a chimeric antigen receptor whose antigen binding domain comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:6, and in a method for treating acute myeloid leukemia, wherein the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0081] In a more preferred embodiment, the FLT3 targeting agent is administered to a patient in need thereof in a T cell expressing a chimeric antigen receptor capable of binding to FLT3, said chimeric antigen receptor being a chimeric antigen receptor whose antigen binding domain comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8, and in a method for treating acute myeloid leukemia, wherein the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0082] In a more preferred embodiment, the FLT3 targeting agent is administered to a patient in need thereof in a method for treating acute myeloid leukemia wherein the T cells express a chimeric antigen receptor capable of binding to FLT3, wherein the chimeric antigen receptor is a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO:2 or a sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto, and wherein the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0083] In a more preferred embodiment, the FLT3 targeting agent is administered to a patient in need thereof in a method for treating acute myeloid leukemia wherein the T cells express a chimeric antigen receptor capable of binding to FLT3, wherein the chimeric antigen receptor is a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO:4 or a sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto, and wherein the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0084] In a further preferred embodiment, the FLT3 targeting agent targets T cells expressing a chimeric antigen receptor capable of binding to FLT3, preferably CD8 + T cells or CD4 + A T cell, wherein the chimeric antigen receptor is a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, preferably a CD8 + T cells or CD4 + and administered to a patient in need thereof in a method for treating acute myeloid leukemia, wherein the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0085] In one embodiment, the kinase inhibitor is a tyrosine kinase inhibitor, preferably a receptor tyrosine kinase inhibitor, more preferably an FLT3 inhibitor.The FLT3 inhibitor according to the present invention can be a type I FLT3 inhibitor or a type II FLT3 inhibitor.In a preferred embodiment, the FLT3 inhibitor is a type II FLT3 inhibitor, preferably midostaurin or quizartinib.In a more preferred embodiment, the FLT3 inhibitor is a type I FLT3 inhibitor, preferably crenolanib.

[0086] In a preferred embodiment, the kinase inhibitor is a FLT3 inhibitor and is administered to a patient in need thereof in a method for treating acute myeloid leukemia, wherein the acute myeloid leukemia cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0087] In a more preferred embodiment, the kinase inhibitor is a FLT3 inhibitor, preferably midostaurin or quizartinib, more preferably crenolanib, and is administered to a patient in need thereof in a method for treating acute myeloid leukemia, wherein acute myeloid leukemia cells express FLT3, preferably mutated FLT3, more preferably FLT3-ITD, and wherein administration of said FLT3 inhibitor results in upregulation of expression of FLT3.

[0088] Methods of treatment and products for use in these methods The present invention relates to FLT3 targeted agents and kinase inhibitors and their use in acute myeloid leukemia as described above.

[0089] In addition to and in accordance with these FLT3 targeting agents and their uses, the present invention also relates to corresponding methods of treatment.

[0090] In one embodiment, the invention relates to a method of administering a FLT3 targeted agent in combination with a kinase inhibitor to a patient in a method for treating acute myeloid leukemia.

[0091] In a more preferred embodiment, the present invention relates to administering a FLT3 targeting agent in combination with a kinase inhibitor to a patient having cancer in need thereof, wherein the FLT3 targeting agent is a T cell expressing a chimeric antigen receptor capable of binding to FLT3 (FLT3 CAR-T cell), wherein the chimeric antigen receptor comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:8, the kinase inhibitor is a FLT3 inhibitor, preferably quizartinib or midostaurin, more preferably crenolanib, the cancer is acute myeloid leukemia, and the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD.

[0092] In a preferred embodiment, the present invention relates to administering a FLT3 targeted agent in combination with a kinase inhibitor to a patient having cancer in need thereof, where the FLT3 targeted agent is a T cell expressing a chimeric antigen receptor capable of binding to FLT3 (FLT3 CAR-T cells), the kinase inhibitor is a FLT3 inhibitor, the cancer is acute myeloid leukemia, and the acute myeloid leukemia tumor cells express FLT3.

[0093] In a more preferred embodiment, the present invention relates to administering a FLT3 targeting agent in combination with a kinase inhibitor to a patient having cancer in need thereof, wherein the FLT3 targeting agent is a T cell expressing a chimeric antigen receptor capable of binding to FLT3 (FLT3 CAR-T cell), wherein the chimeric antigen receptor comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:8, the kinase inhibitor is a FLT3 inhibitor, preferably quizartinib or midostaurin, more preferably crenolanib, the cancer is acute myeloid leukemia, the acute myeloid leukemia tumor cells express FLT3, and the tumor cells preferably express a mutated FLT3, more preferably FLT3-ITD.

[0094] In a further preferred embodiment, the present invention relates to administering a kinase inhibitor to a patient having cancer in need thereof, wherein the kinase inhibitor is a FLT3 inhibitor, preferably quizartinib or midostaurin, more preferably crenolanib, the cancer is acute myeloid leukemia, and the acute myeloid leukemia tumor cells express FLT3, preferably a mutated FLT3, more preferably FLT3-ITD, and the FLT3 inhibitor is administered prior to, simultaneously with, or after administration of a FLT3 targeted agent, thereby causing upregulation of FLT3 expression and increased antigen density on the tumor cell surface, wherein said antigen is a portion of the FLT3 extracellular domain. In this embodiment, the FLT3 targeting agent administered before, simultaneously with, or after administration of the FLT3 inhibitor is a T cell expressing a chimeric antigen receptor capable of binding to FLT3 (FLT3 CAR-T cell), the chimeric antigen receptor preferably comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:8, and the antigen to which the FLT3 CAR-T cell binds is a part of the FLT3 extracellular domain, which is upregulated and increases the antigen density in acute myeloid leukemia tumor cells by the FLT3 inhibitor. Thus, according to this embodiment, the combined administration of an FLT3 inhibitor causing upregulation of FLT3 on the cell surface of acute myeloid tumor cells and increasing the antigen density of the FLT3 extracellular domain and an FLT3 targeting agent, which is a FLT3 CAR-T cell binding to said FLT3 extracellular domain, can lead to an improved acute myeloid leukemia therapy compared to monotherapy using either the FLT3 inhibitor or the FLT3 CAR-T cell alone. Thus, according to this embodiment, the combined administration of a FLT3 inhibitor and a FLT3 targeted agent, FLT3 CAR-T cells, achieves surprising and unexpected synergistic effects that provide improvements in the treatment of acute myeloid leukemia.

[0095] In another embodiment, the invention relates to administering a FLT3 targeting agent in combination with a kinase inhibitor to a patient with acute myeloid leukemia, where the FLT3 targeting agent is an antibody or fragment thereof capable of binding to FLT3, the kinase inhibitor is a FLT3 inhibitor, and the acute myeloid leukemia tumor cells express FLT3.

[0096] In a more preferred embodiment, the present invention relates to administering a FLT3 targeting agent in combination with a kinase inhibitor to a patient with acute myeloid leukemia, wherein the FLT3 targeting agent is an antibody or a fragment thereof, the antibody or a fragment thereof comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:8, the kinase inhibitor is a FLT3 inhibitor, preferably quizartinib or midostaurin, more preferably crenolanib, and the acute myeloid leukemia tumor cells express FLT3, preferably the tumor cells express a mutated FLT3, more preferably FLT3-ITD.

[0097] FLT3 targeting agents according to the present invention and their combination with kinase inhibitors The present invention encompasses a combination of an FLT3 targeted agent and a kinase inhibitor for use in a method of treating cancer in a human patient, the method comprising co-administering the FLT3 targeted agent and the kinase inhibitor to the human patient.

[0098] array The amino acid sequences referred to in this application are as follows (ordered from N-terminus to C-terminus; expressed in one letter amino acid code): SEQ ID NO:2 (Sequence of 4G8 FLT3 CAR): QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQKFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDFW GQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFG VYFCQQSNTWPYTFGGGTKLEIKRESKYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID NO:4 (Sequence of BV10 FLT3 CAR): QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGLHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARKGGIYYANHYYAMD YWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPSSLSVSAGEKVTMSCKSSQSLLNSGNQKNYMAWYQQKPGQPPKLLIYGASTRESGVPDRFTGSGSGTDFTLTISSV QAEDLAVYYCQNDHSYPLTFGAGTKLELKRESKYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID NO:5 (4G8 heavy chain variable domain (VH)): QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQKFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDFWGQGTTLTVSS SEQ ID NO:6 (4G8 light chain variable domain (VH)): DIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSNTWPYTFGGGTKLEIKR SEQ ID NO:7 (BV10 heavy chain variable domain (VH)): QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGLHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARKGGIYYANHYYAMDYWGQGTSVTVSS SEQ ID NO:8 (BV10 light chain variable domain (VH)): DIVMTQSPSSLSVSAGEKVTMSCKSSQSLLNSGNQKNYMAWYQQKPGQPPKLLIYGASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDHSYPLTFGAGTKLELKR SEQ ID NO:9 (GMCSF signal peptide): MLLLVTSLLLCELPHPAFLLIP SEQ ID NO:10 (4(GS)×3 linker): GGGGSGGGGSGGGGS SEQ ID NO:11 (IgG4 hinge domain): ESKYGPPCPPCP SEQ ID NO: 12 (CD28 transmembrane domain): MFWVLVVVGGVLACYSLLVTVAFIIFWV SEQ ID NO:13 (CD28 costimulatory domain): RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS SEQ ID NO:14 (CD3z signaling domain): RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID NO:15 (T2A ribosomal skipping sequence): LEGGGEGRGSLLTCGDVEENPGPR SEQ ID NO:16 (EGFRt): RKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCK ATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFM

[0099] The nucleic acid sequences referred to in this application are as follows (5' to 3' order; represented according to the standard nucleic acid code): SEQ ID NO:1 (sequence of 4G8 FLT3 CAR): SEQ ID NO:3 (Sequence of BV10 FLT3 CAR): EXAMPLES

[0100] Further aspects and details of the present invention are illustrated by the following non-limiting examples.

[0101] Example 1 Materials and Methods Human subjects Peripheral blood was obtained from healthy donors and adult AML patients after written informed consent was obtained for participation in a study protocol approved by the Institutional Review Board of the participating institutions.

[0102] Primary AML cells Primary AML cells were maintained in RPMI-1640 supplemented with 10% human serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and a cytokine cocktail including IL-4 (1000 IU / mL), granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 ng / mL), stem cell factor (5 ng / mL), and tumor necrosis factor (TNF)-α (10 ng / mL).

[0103] Tumor cell lines Human leukemia cell lines MOLM-13 (ACC 554), THP-1 (ACC 16), MV4;11 (ACC 102), and K562 (ACC 10) were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) and cultured in RPMI-1640 supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and 100 U / mL penicillin / streptomycin. All cell lines were transduced with a lentiviral vector encoding a firefly luciferase (ffluc)_green fluorescent protein (GFP) transgene to allow detection by flow cytometry (GFP) and bioluminescence imaging in mice (ffLuc), and bioluminescence-based cytotoxicity assays. K562 / FLT3 was generated by retroviral transduction with the full-length human FLT3 gene.

[0104] Flow cytometry analysis of FLT3 expression Cell surface FLT3 expression (CD135) was analyzed using a conjugated mouse anti-human FLT3 mAb (clone 4G8, BD Pharmagin, BD Biosciences, Germany) and a mouse IgG1 isotype control (BD Pharmagin). 6 The cells were washed, resuspended in 100 μL PBS / 0.5% fetal bovine serum, and stained with 5 μL anti-FLT3 mAb or isotype for 30 min at 4°C.

[0105] CAR construction FLT3-specific 4G8 mAb12 V H Segment and V L A codon-optimized targeting domain containing the segment was synthesized (GeneArt, ThermoFisher, Regensburg, Germany) and fused in-frame to a CAR scaffold containing a short IgG4-Fc hinge spacer, a CD28 transmembrane and costimulatory portion, and a CD3z, T2A element, and an EGFRt transduction marker (Figure 1).32~34 The entire transgene was encoded in the lentiviral vector epHIV7 and expressed under the control of the EF1 / HTLV hybrid promoter. 34、35 Similarly, targeting domains specific for CD19 (clone FMC63) and CD123 (clone 32716) were used to generate CD19 CARs and CD123 CARs, respectively. 32、33、36、37 .

[0106] EGFR preparation of CAR modified T cells CD4 activated with CD3 / 28 beads (ThermoFisher) + T cells and CD8 + Lentiviral gene transfer into T cells was performed 1 day after bead stimulation at a multiplicity of infection (MOI) of 5. T cells were cultured in RPMI-1640 supplemented with 10% human serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 50 U / mL recombinant human interleukin (IL)-2 (Proleukine, Novartis, Basel, Switzerland). 32 CAR-transduced T cells were enriched using biotinylated anti-EGFR mAb (ImClone Systems Inc.) and anti-biotin beads (Miltenyi), followed by a rapid expansion protocol. 38 or for CD19 CAR-T cells, irradiated (80 Gy) CD19 + Using antigen-specific stimulation with feeder cells 38 It increased.

[0107] Flow cytometric analysis of T cells Primary AML and peripheral blood mononuclear cells (PBMCs) were stained with one or more of the following conjugated mAbs: CD3, CD19, CD34, CD38, CD33, CD45, CD123, CD135 and corresponding isotype controls (Miltenyi, Bergisch-Gladbach, Germany / BD, Heidelberg, Germany / Biolegend, London, UK). CAR-modified and non-transduced T cells were stained with one or more of the following conjugated mAbs for live / dead cell discrimination: CD4, CD8, CD45RA, CD45RO, CD62L, and 7-AAD (Miltenyi / BD / Biolegend). CAR-transduced (i.e., EGFRt + ) T cells were detected by staining with an in-house biotinylated anti-EGFR antibody (EZ-Link™ Sulfo-NHS-SS-Biotin, Thermofisher Scientific, IL, according to manufacturer's instructions) and streptavidin-PE. Flow analysis was performed on a FACSCanto (BD), and data were analyzed using FlowJo software v9.0.2 (Treestar, Ashland, OR).

[0108] Analysis of CAR-T cell function in vitro Functional assays were performed as previously described 32、33、39~41 Briefly, target cells expressing firefly luciferase (ffLuc) were plated at 5 × 10 cells per well. 3 Target cells were incubated in triplicate with effector T cells at various effector to target (E:T) ratios. After 4 h of incubation, luciferin substrate was added to the co-cultures and the reduction in luminescence signal in wells containing target and T cells was measured using a luminometer (Tecan, Mannedorf, Switzerland) and compared to target cells alone. Specific lysis was calculated using the standard formula: 42 To analyze cytokine secretion, 50 x 10 T cells were 350 × 10 T cells were plated in triplicate wells at a 2:1 ratio with target cells and incubated for 24 h before measuring IFN-γ and IL-2 production in the supernatants by ELISA (Biolegend). 3 T cells were labeled with 0.2 μM carboxyfluorescein succinimidyl ester (CFSE, ThermoFisher), washed, and plated in triplicate wells at a 2:1 ratio with target cells in medium without exogenous cytokines. After 72 h of incubation, cells were labeled with anti-CD8 / CD4 mAb and 7-AAD to exclude dead cells from the analysis. Samples were analyzed by flow cytometry, and viable T cell division was assessed by CFSE dilution. The cytolytic activity of CAR-modified and control T cells against primary AML cells was analyzed in a FACS-based cytotoxicity assay. T cells and AML cells were plated in 96-well plates and target cells at 10 × 10 per well. 3 The cells were seeded at effector:target (E:T) ratios ranging from 20:1 to 1:1. After 4–24 h, cultures were aspirated and stained with 7-AAD to distinguish live from dead cells and with anti-CD3 / anti-CD33 / anti-CD45 mAbs to distinguish T cells from AML cells. To quantify the number of remaining viable AML cells, 123-counting beads (e-bioscience, San Diego, CA) were used according to the manufacturer's instructions. Flow cytometry analysis was performed on a FACS Canto II (BD) and data were analyzed using FlowJo software (Treestar).

[0109] In vivo experiments All experiments were approved by the Institutional Animal Care and Use Committee of the participating institutions. scid Il2rg tm1Wjl / SzJ(NSG) mice (female, 6-8 weeks old) were purchased from Charles River or bred in-house. Mice were transfected with ffluc_GFP on day 0. +MOLM-13 AML cells 1×10 6 5 × 10 T cells were inoculated by tail vein injection on day 7. 6 Mice were dosed with a single dose of 100 mg / kg (in 200 μL of PBS / 0.5% FCS) via tail vein injection. Crenolanib [15 mg / kg; 200 μL of 30% glycerol formal (Sigma Aldrich, Munich, Germany)] was administered intraperitoneally (i.p.) Monday through Friday for three consecutive weeks. After i.p. administration of D-luciferin substrate (0.3 mg / g body weight) (Biosynth, Staad, Switzerland), AML progression / regression was assessed by graded bioluminescence imaging using an IVIS Lumina imaging system (Perkin Elmer, Waltham, Massachusetts). Data were analyzed using Living Image software (Perkin Elmer).

[0110] Treatment of MOLM-13 AML cells with FLT3 inhibitors MOLM-13 were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 10 nM crenolanib or 1 nM quizartinib or 10 nM midostaurin. Complete medium changes were performed every 7 days, and MOLM-13 cells were cultured at 1 × 10 per mL of medium. 6 The cells were adjusted to 100 μg / well and 2 mL of this cell suspension was plated per well of a 48-well plate (Costar, Corning, NJ). After 2–3 weeks of culture with 10 nM midostaurin, MOLM-13 cells were exposed to exponentially increasing concentrations of midostaurin over the next 8–10 weeks until 50 nM midostaurin was reached.

[0111] Medicines and Reagents Crenolanib, quizartinib (Selleck Chemicals, Houston, TX), and midostaurin (Novartis, Basel, Switzerland / Selleck Chemicals, Houston, TX / Sigma-Aldrich, Steinheim, Germany) were reconstituted in dimethyl sulfoxide (DMSO) and then diluted in culture medium or 30% glycerol formal (Sigma Aldrich, Munich, Germany) for in vitro or in vivo experiments, respectively.

[0112] statistical analysis Statistical analysis was performed using Prism software v6.07 (GraphPad). Unpaired Student's t test was used to analyze data obtained in vitro. Log-rank (Mantel-Cox) test was performed to analyze survival differences observed in in vivo experiments. Differences with p values ​​<.05 were considered statistically significant.

[0113] result: FLT3 CAR-T cells were compared with FLT3 wild-type cells and FLT3-ITD cells. + Eliminate AML cells A CAR transgene containing a targeting domain derived from the FLT3-specific mAb 4G8 was constructed and administered to healthy donors and AML patients (n=6) for CD4 + T cells and CD8 + Gene transfer into T cells was performed. FLT3 CAR-transduced T cells were enriched to >90% purity using the EGFRt transduction marker, followed by expansion and functional testing (Figure 2). First, CD4 + FLT3 CAR-T cells and CD8 + Specific recognition of FLT3 surface protein by FLT3 CAR-T cells was confirmed by comparing native K562 (phenotype: FLT3 -) and K562 target cells transduced to stably express wild-type FLT (K562 / FLT3) (Figure 3). Then, the AML cell lines THP-1 (FLT3 wild-type), MOLM-13 (FLT3-ITD + / - ) and MV4;11(FLT3-ITD + / + ) were included in our analysis, and for each of the cell lines, CD8 + A high level of specific cytolytic activity of FLT3 CAR-T cells was confirmed (Figure 4A, B). + FLT3 CAR-T cells and CD8 + FLT3 CAR-T cells produced effector cytokines, including IFN-γ and IL-2, and proliferated productively after stimulation with each of the AML cell lines, whereas control T cells from the same respective donors showed only background reactivity (Figures 5, 6). Because FLT3 CAR binds to an epitope within the extracellular domain of FLT3, recognition of AML cells was independent of the mutational status of the intracellular tyrosine kinase domain, but instead correlated with the antigen density of FLT3 surface protein on target cells as assessed by mean fluorescence intensity (MFI) (THP-1 ~ MOLM-13>MV4; 11) (Figure 4A).

[0114] FLT3-ITD in patient-derived FLT3 CAR-T cells + Potent activity against primary AML cells was also confirmed, with potent cytolytic activity leading to eradication of >80% of AML blasts in as little as 4 hours (E:T ranging from 20:1 to 1:1) (Figure 4A,B). Notably, the antileukemic activity of FLT3 CAR-T cells against primary AML blasts was comparable to T cells expressing a similarly engineered CAR specific for the alternative AML target antigen CD123 (Figure 4B).

[0115] FLT3 CAR-T cells induce durable AML remissions in vivo in a xenograft model Experiments were performed to analyze the function of FLT3 CAR-T cells in vivo in a xenograft model of AML in immunodeficient NSG mice. After inoculation with ffLuc_GFP-transduced MOLM-13 AML cells, mice rapidly developed systemic leukemia with leukemic cells circulating in the peripheral blood and infiltration of the bone marrow and spleen (Figure 7A). Leukemia-bearing mice were cultured in a 10-well plate with a comparable proportion of CD4 + T cells and CD8 + Consisting of T cells, FLT3 CAR modified T cells or non-transduced T cells 5 x 10 6 The mice were treated with a single dose of FLT3 CAR-T cells or were not treated. A strong anti-leukemia effect was confirmed in all mice that showed engraftment of FLT3 CAR-T cells. In these mice, the number of FLT3 CAR-T cells increased during the anti-leukemia response and could be easily detected in the peripheral blood at multiple time points; as well as in the bone marrow and spleen at the end of the experiment, confirming their persistence for more than 3 weeks after adoptive transfer (Figures 7B, 8A). Stepwise bioluminescence imaging confirmed strong anti-leukemia activity in all mice engrafted with FLT3 CAR-T cells, while mice that failed to engraft CAR-T cells, mice treated with control T cells, and untreated mice showed rapid leukemia progression (Figures 7A, 8B). Further flow cytometry analysis confirmed the sustained complete remission of AML cells derived from bone marrow and spleen (Figure 9A). Kaplan-Meier analysis showed significantly longer overall survival after treatment with FLT3 CAR-T cells compared to control T cells and no treatment (p<.05) (Figure 9B). All mice that responded to FLT3 CAR-T cell therapy were 100% responsive to CAR-T cell therapy, consistent with previous reports of CAR-T cell therapy in the NSG mouse model. 37、43 Consistent with this, it is noteworthy that relapse of extramedullary late stage disease was also observed (Figure 7A). Expression of FLT3 in AML cells derived from extramedullary late stage disease manifestations was detectable at levels similar to native MOLM-13 cells, i.e., no antigen loss occurred. Overall, our data demonstrate that FLT3 CAR-T cells inhibit FLT3 wild-type and FLT3-ITD cells in vitro and in vivo. +It is shown to confer potent anti-leukemic activity against AML cell lines and primary AML cells.

[0116] Midostaurin is a treatment for FLT3-ITD + Induces increased FLT3 surface protein expression in AML cells FLT3-ITD + Findings from clinical trials in patients with AML are the upregulation of FLT3 as a compensatory mechanism in AML blasts to counteract the effects of FLT3 inhibitors, a mechanism that we hypothesize could be exploited to enhance the anti-leukemia efficacy of FLT3 CAR-T cells. 24、25 . Naive MOLM-13 AML cells (MOLM-13 Native )(FLT3-ITD + / - ) in combination with the FLT3 inhibitor midostaurin (MOLM-13 mido After 2–3 weeks of drug exposure, MOLM-13 mido FLT3 expression was analyzed by flow cytometry and as assessed by MFI in MOLM-13 Native We indeed observed significantly higher levels of FLT3 surface protein compared to MOLM-13 cells (n=2 experiments, p<.05) (Figure 10A). Furthermore, we slowly increased the midostaurin concentration from 10 nM to 50 nM over the next 8-10 weeks and observed a further increase in FLT3 expression (Figure 10B). Interestingly, cessation of midostaurin led to a decline in FLT3 expression in MOLM-13 cells to baseline or slightly below baseline levels within 2 days, but it rose again upon re-exposure to the drug (Figure 10C). After primary exposure to midostaurin, MOLM-13 cells showed a significant increase in FLT3 expression over a period of approximately 2 weeks. Native Compared with MOLM-13 cells mido A moderate cytotoxic effect and slower expansion of cells was observed. However, the cytotoxic effect of midostaurin subsequently disappeared, and MOLM-13 cells were not cultured despite continued supplementation of the culture medium. mido The proliferation of the cells was accelerated, indicating that these cells had acquired resistance.

[0117] Increased FLT3 expression upon exposure to midostaurin was observed in MV4;11 AML cells (FLT3-ITD + / + ), but not in several cell lines expressing wild-type FLT3, i.e., THP-1 AML cells and K562 erythromyelogenous leukemia, suggesting that the upregulation of FLT3 expression in response to midostaurin treatment is due to the FLT3-ITD + This suggests that this occurs specifically in AML cells (FIG. 10A, B). In contrast to FLT3, CD33 expression in MOLM-13 was slightly reduced, whereas a significant reduction in CD123 expression was observed (FIG. 11).

[0118] AML MOLM-13 mido High FLT3 expression in cells leads to enhanced anti-leukemia reactivity of FLT3 CAR-T cells in vitro MOLM-13 mido We predicted that high FLT3 expression in cells would enhance recognition by FLT3 CAR-T cells. Since FLT3 expression is rapidly regulated upon exposure to and cessation of exposure to midostaurin, it would be best to administer FLT3 CAR-T cells simultaneously with the drug to maximize synergistic anti-leukemia effects. It has been shown that TKIs can interfere with T cell signaling, and therefore it was confirmed that midostaurin itself does not affect the function of FLT3 CAR-T cells. We then performed a 3D model of midostaurin-pretreated MOLM-13 cells in the presence of the drug. mido We evaluated the anti-leukemia reactivity of FLT3 CAR-T cells against native MOLM-13 at an E:T ratio of 10:1. native cells (80.3 ± 2.0), compared with MOLM-13 mido A significantly higher cytolytic activity of CD8+FLT3 CAR-T cells against IL-1 was observed (90.0±0.9) (p<0.05) (Figure 12). Furthermore, at a relatively low E:T ratio, CD8 +A 1.4-fold increase in cytolytic activity of FLT3 CAR-T cells (75.6±2.5 vs. 53.5±2.2 at an E:T ratio of 5:1) and a 1.5-fold increase (50.6±1.3 vs. 33.0±3.4 at an E:T ratio of 2.5:1) were observed (Figure 12). native MOLM-13 compared to cells mido We analyzed the specific cytokine production by FLT3 CAR-T cells against IL-13. In fact, FLT3-CAR T cells increased IFN-γ production by 2.3 times (MOLM-13 mido Against MOLM-13 nattive , 2934.0±26.0 pg / mL vs. 1263.0±11.0 pg / mL) and 12.4-fold increased IL-2 production (MOLM-13 mido Against MOLM-13 nattive , 434.0±23.0 pg / mL vs. 35.0±6.0 pg / mL) was observed (Figure 13A). native Compared with MOLM-13 cells mido The proliferation index was 1.8 times higher than that of the control (% proliferation, MOLM-13 mido Against MOLM-13 nattive , 59.4 vs. 31.3) (Figure 13B). mido The percentages of T cells that expanded at least three-fold and at least four-fold to MOLM-13 were 23.9 and 31.4, respectively, compared with MOLM-13 native 10.5 and 19.3, respectively, for (FIG. 13B), demonstrating a significant gain of function.

[0119] Crenolanib is a treatment for FLT3-ITD + Induces increased FLT3 surface protein expression in AML cells FLT3-ITD + Findings from clinical trials in patients with AML are the upregulation of FLT3 as a compensatory mechanism in AML blasts to counteract the effects of FLT3 inhibitors, a mechanism that we hypothesize could be exploited to enhance the anti-leukemia efficacy of FLT3 CAR-T cells. 24、25. Naive MOLM-13 AML cells (MOLM-13 Native )(FLT3-ITD + / - ) was administered in combination with the FLT3 inhibitor crenolanib (MOLM-13) at a clinically achievable serum level of 10 nM. Creno ) were cultured in the presence of 27、44 MOLM-13 cells were analyzed by flow cytometry 5 days after exposure to drugs. Creno Analyzing FLT3 expression in MOLM-13 as assessed by MFI Native We indeed observed significantly higher levels of FLT3 surface protein compared to MOLM-13 cells (n=3 experiments, p<.05) (Figure 14A). Interestingly, cessation of crenolanib led to a decline in FLT3 expression in MOLM-13 cells to baseline levels within 2 days, but it rose again upon re-exposure to the drug (Figure 14B). After primary exposure to crenolanib, MOLM-13 cells were significantly higher for approximately 7 days. Native Compared with MOLM-13 cells Creno A moderate cytotoxic effect and slower expansion of cells was observed (Figure 15A, B). However, the cytotoxic effect of crenolanib subsequently disappeared, and MOLM-13 cells were not affected, despite continued supplementation of the culture medium. Creno The proliferation of the cells was accelerated, suggesting that these cells had acquired resistance.

[0120] Increased FLT3 expression upon exposure to crenolanib was observed in MV4;11 AML cells (FLT3-ITD + / + ), but not in several cell lines expressing wild-type FLT3, i.e., THP-1 AML cells, JeKo-1 mantle cell lymphoma, and K562 erythromyeloid leukemia, suggesting that upregulation of FLT3 expression in response to crenolanib treatment is consistent with FLT3-ITD. + This suggests that this occurs specifically in AML cells (Figure 14A). In contrast to FLT3, CD33 and CD123 expression was not affected or increased by crenolanib in either MOLM-13 or MV4;11 cells (Figure 16).

[0121] High FLT3 expression in MOLM-13 AML cells treated with crenolanib leads to enhanced anti-leukemia reactivity of FLT3 CAR-T cells in vitro MOLM-13 Creno We sought to analyze whether the high antigen density of FLT3 in MOLM-13 enhances its recognition by FLT3 CAR-T cells. Our previous data showed rapid modulation of FLT3 expression upon exposure to and cessation of exposure to crenolanib (Figure 15B), which may enhance the recognition of FLT3 in MOLM-13 Creno These results suggest that the maximum reactivity of FLT3 CAR-T cells against IL-1 is achieved in the presence of the drug. TKIs are known to be capable of interfering with T cell activation and function. 45、46 , thus confirming that crenolanib itself does not affect the effector function of FLT3 CAR-T cells.

[0122] In fact, at an E:T ratio of 10:1, native MOLM-13 native Cells (68.0 ± 0.9) compared with MOLM-13 creno VS CD8 + A superior cytolytic activity of FLT3 CAR-T cells was observed (74.7±0.8) (p<0.05) (Figure 17). Furthermore, at a relatively low E:T ratio, CD8 + Two-fold increase in cytolytic activity of FLT3 CAR-T cells (at an E:T ratio of 5:1, MOLM-13 creno Against MOLM-13 native A 2.5-fold increase (46.4±4.9 vs. 18.5±9.3 at an E:T ratio of 2.5:1) and a 2.5-fold increase (46.4±4.9 vs. 18.5±9.3 at an E:T ratio of 2.5:1) were observed ( FIG. 17 ). native MOLM-13 compared to cells creno We analyzed cytokine production by FLT3 CAR-T cells against IL-13. In fact, FLT3-CAR T cells increased IFN-γ production by 1.4 times (MOLM-13 creno Against MOLM-13 native , 2121.1 ± 135.1 pg / mL vs. 1523.0 ± 229.8 pg / mL) and 3.9-fold increased IL-2 production (MOLM-13 crenoAgainst MOLM-13 native , 135.8±16.5 pg / mL vs. 34.7±8.8 pg / mL) was observed (Figure 18A). creno The percentages of T cells that expanded at least three-fold and at least four-fold to MOLM-13 were 39.2 and 28.6, respectively, compared with MOLM-13 native 29.0 and 26.5, respectively (FIG. 18B), demonstrating a significant gain of function.

[0123] Quizartinib is a treatment for FLT3-ITD + Induces increased FLT3 surface protein expression in AML cells FLT3 - ITD + Findings from clinical trials in patients with AML are the upregulation of FLT3 as a compensatory mechanism in AML blasts to counteract the effects of FLT3 inhibitors, a mechanism that we hypothesize could be exploited to enhance the anti-leukemia efficacy of FLT3 CAR-T cells. 24、25 . Naive MOLM-13 AML cells (MOLM-13 Native )(FLT3-ITD + / - ) were cultured in the presence of the FLT3 inhibitor quizartinib at a clinically achievable serum level of 1 nM (MOLM-13 Quiza ) 27、44 MOLM-13 Quiza FLT3 expression in MOLM-13 mice was analyzed by flow cytometry 5 days after exposure to drugs, as assessed by MFI. Native We indeed observed significantly higher levels of FLT3 surface protein compared to MOLM-13 cells (n=3 experiments, p<.05) (Figure 19A). Interestingly, cessation of quizartinib led to a decline in FLT3 expression in MOLM-13 cells to baseline levels within 2 days, but it rose again upon re-exposure to the drug (Figure 19B). After primary exposure to quizartinib, MOLM-13 cells were significantly higher for approximately 7 days. Native Compared with MOLM-13 cells QuizaA moderate cytotoxic effect and slower expansion of cells was observed. However, the cytotoxic effect of quizartinib subsequently disappeared, despite continued supplementation of the culture medium, and MOLM-13 Quiza The proliferation of the cells was accelerated, suggesting that these cells had acquired resistance.

[0124] Increased FLT3 expression upon exposure to quizartinib was observed in MV4;11 AML cells (FLT3-ITD + / + ), but not in several cell lines expressing wild-type FLT3, i.e., THP-1 AML cells, JeKo-1 mantle cell lymphoma, and K562 erythromyeloid leukemia, suggesting that upregulation of FLT3 expression in response to quizartinib treatment is consistent with FLT3-ITD. + This suggests that this occurs specifically in AML cells (Figure 19B). In contrast to FLT3, CD33 expression and CD123 expression were not affected or increased by quizartinib in either MOLM-13 or MV4;11 cells (Figure 20).

[0125] AML MOLM-13 quiza High FLT3 expression in cells leads to enhanced anti-leukemia reactivity of FLT3 CAR-T cells in vitro MOLM-13 quiza We predicted that high FLT3 expression in quizartinib-pretreated MOLM-13 cells would enhance their recognition by FLT3 CAR-T cells. Because FLT3 expression is rapidly regulated upon exposure to and cessation of exposure to quizartinib, it may be best to administer FLT3 CAR-T cells simultaneously with the drug to maximize synergistic anti-leukemia effects. We then performed a multicenter study of quizartinib-pretreated MOLM-13 cells in the presence of the drug. quiza We evaluated the anti-leukemia reactivity of FLT3 CAR-T cells against leukemia-related tumors.

[0126] In fact, at an E:T ratio of 10:1, native MOLM-13 native Cells (47.3 ± 5.6) compared with MOLM-13 quiza CD8 against +A superior cytolytic activity of FLT3 CAR-T cells was observed (67.9±2.4) (p<0.05) (Figure 21). Furthermore, at a relatively low E:T ratio, CD8 + 1.6-fold increase in cytolytic activity of FLT3 CAR-T cells (at an E:T ratio of 5:1, MOLM-13 quiza Against MOLM-13 nattive A 17.7-fold increase (25.6±4.1 vs. 1.4±2.0 at an E:T ratio of 2.5:1) was observed (Figure 21). Next, native MOLM-13 native Compared with MOLM-13 cells quiza We analyzed cytokine production by FLT3 CAR-T cells against MOLM-13. In fact, FLT3-CAR T cells produced 1.4-fold more IFN-γ ( quiza Against MOLM-13 nattive , 1711.0±36.0pg / mL vs. 1263.1±11.0pg / mL) and 1.9-fold increased IL-2 production (MOLM-13 quiza Against MOLM-13 nattive , 68.0±3.0 pg / mL vs. 35.0±6.0 pg / mL) was observed (Figure 22A). quiza The percentages of T cells that expanded at least three-fold and at least four-fold to MOLM-13 were 33.9 and 28.7, respectively, compared with MOLM-13 native 29.0 and 25.9, respectively (FIG. 22B), demonstrating a significant gain of function.

[0127] FLT3 CAR-T cells and the FLT3 inhibitor crenolanib act synergistically in mediating AML regression in vivo This prompted us to investigate the anti-leukemic effect of the combination of FLT3 CAR-T cells and crenolanib in the MOLM-13 / NSG xenograft model. Mice were treated with MOLM-13 nativeAML cells were inoculated and treated with either FLT3 CAR-T cells alone, Crenolanib alone (15 mg per kg body weight, ip injection, qd), FLT3 CAR-T cells and Crenolanib combination treatment, or left untreated on day 7. Potent anti-leukemia efficacy was observed in mice that received FLT3 CAR-T cells and Crenolanib combination treatment (Figure 23A). Mice receiving the combination of FLT3 CAR-T cells and crenolanib showed superior engraftment and in vivo expansion of FLT3 CAR-T cells by flow cytometry (Figure 23B), higher response rates (combination: n=8 / 8, 100% vs. FLT3 CAR-T cells alone, n=6 / 8, 75% vs. crenolanib alone, n=0 / 8, 0% vs. no treatment, n=0 / 0, 0%), faster and deeper remissions as assessed by bioluminescence imaging (Figures 23A, 24A), and improved overall survival compared to FLT3 CAR-T cell and crenolanib monotherapy, respectively, and no treatment (p<.05) (Figure 24B). Crenolanib monotherapy had only a minute anti-leukemic effect, and FLT3 was uniformly and strongly upregulated in MOLM-13 cells harvested from peripheral blood and bone marrow at the experimental endpoint, consistent with our previous in vitro observations (Figure 25A). Combination treatment also delayed extramedullary late-stage disease in mice. At the experimental endpoint, peripheral blood, bone marrow, and spleen in mice treated with FLT3 CAR-T cells / Crenolanib combination and mice treated with FLT3 CAR-T cell monotherapy did not contain AML cells, whereas mice treated with Crenolanib monotherapy and untreated mice showed extensive leukemic infiltration (Figure 25B). Collectively, the data suggest that FLT3 CAR-T cells and Crenolanib can be used synergistically in combination therapy to prevent FLT3-ITD in vitro and in vivo. + It is shown that it can confer a potent anti-leukemic effect on AML cells.

[0128] Example 2 Materials and Methods: Human subjects Peripheral blood was obtained from healthy donors and adult AML patients after written informed consent was obtained for participation in a study protocol approved by the Institutional Review Board of the participating institutions.

[0129] Primary AML cells Primary AML cells were maintained in RPMI-1640 supplemented with 10% human serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and a cytokine cocktail including IL-4 (1000 IU / mL), granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 ng / mL), stem cell factor (5 ng / mL), and tumor necrosis factor (TNF)-α (10 ng / mL).

[0130] Tumor cell lines Human leukemia cell lines MOLM-13 (ACC 554), THP-1 (ACC 16), MV4;11 (ACC 102), and K562 (ACC 10) were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) and cultured in RPMI-1640 supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and 100 U / mL penicillin / streptomycin. All cell lines were transduced with a lentiviral vector encoding a firefly luciferase (ffluc)_green fluorescent protein (GFP) transgene to allow detection by flow cytometry (GFP) and bioluminescence imaging in mice (ffLuc), and bioluminescence-based cytotoxicity assays. K562 / FLT3 was generated by retroviral transduction with the full-length human FLT3 gene.

[0131] Flow cytometry analysis of FLT3 expression Cell surface FLT3 expression (CD135) was analyzed using a conjugated mouse anti-human FLT3 mAb (clone 4G8, BD Pharmagin, BD Biosciences, Germany) and a mouse IgG1 isotype control (BD Pharmagin). 6 The cells were washed, resuspended in 100 μL PBS / 0.5% fetal bovine serum, and stained with 5 μL anti-FLT3 mAb or isotype for 30 min at 4°C.

[0132] CAR construction FLT3-specific BV10 mAb 12 V H Segment and V L A codon-optimized targeting domain containing the segment was synthesized (GeneArt, ThermoFisher, Regensburg, Germany) and fused in-frame to a CAR scaffold containing a short IgG4-Fc hinge spacer, a CD28 transmembrane and costimulatory portion, and a CD3z, T2A element, and an EGFRt transduction marker (Figure 1). 32~34 The entire transgene was encoded in the lentiviral vector epHIV7 and expressed under the control of the EF1 / HTLV hybrid promoter. 34、35 Similarly, targeting domains specific for CD19 (clone FMC63) and CD123 (clone 32716) were used to generate CD19 CARs and CD123 CARs, respectively. 32、33、36、37 .

[0133] Preparation of CAR-modified T cells CD4 activated with CD3 / 28 beads (ThermoFisher) + T cells and CD8 +Lentiviral gene transfer into T cells was performed 1 day after bead stimulation at a multiplicity of infection (MOI) of 5. T cells were cultured in RPMI-1640 supplemented with 10% human serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 50 U / mL recombinant human interleukin (IL)-2 (Proleukiine, Novartis, Basel, Switzerland). 32 CAR-transduced T cells were enriched using biotinylated anti-EGFR mAb (ImClone Systems Inc.) and anti-biotin beads (Miltenyi), followed by a rapid expansion protocol. 38 or for CD19 CAR-T cells, irradiated (80 Gy) CD19 + Using antigen-specific stimulation with feeder cells 38 It increased.

[0134] Flow cytometric analysis of T cells Primary AML and peripheral blood mononuclear cells (PBMCs) were stained with one or more of the following conjugated mAbs: CD3, CD19, CD34, CD38, CD33, CD45, CD123, CD135 and corresponding isotype controls (Miltenyi, Bergisch-Gladbach, Germany / BD, Heidelberg, Germany / Biolegend, London, UK). CAR-modified and non-transduced T cells were stained with one or more of the following conjugated mAbs for live / dead cell discrimination: CD4, CD8, CD45RA, CD45RO, CD62L, and 7-AAD (Miltenyi / BD / Biolegend). CAR-transduced (i.e., EGFRt +) T cells were detected by staining with an in-house biotinylated anti-EGFR antibody (EZ-Link™ Sulfo-NHS-SS-Biotin, Thermofisher Scientific, IL, according to manufacturer's instructions) and streptavidin-PE. Flow analysis was performed on a FACSCanto (BD), and data were analyzed using FlowJo software v9.0.2 (Treestar, Ashland, OR).

[0135] Analysis of CAR-T cell function in vitro Functional assays were performed as previously described 32、33、39~41 Briefly, target cells expressing firefly luciferase (ffLuc) were plated at 5 × 10 cells per well. 3 Target cells were incubated in triplicate with effector T cells at various effector to target (E:T) ratios. After 4 h of incubation, luciferin substrate was added to the co-cultures and the reduction in luminescence signal in wells containing target and T cells was measured using a luminometer (Tecan, Mannedorf, Switzerland) and compared to target cells alone. Specific lysis was calculated using the standard formula: 42 To analyze cytokine secretion, 50 x 10 T cells were 3 50 × 10 T cells were plated in triplicate wells at a 2:1 ratio with target cells and incubated for 24 h before measuring IFN-γ and IL-2 production in the supernatants by ELISA (Biolegend). 3T cells were labeled with 0.2 μM carboxyfluorescein succinimidyl ester (CFSE, ThermoFisher), washed, and plated in triplicate wells at a 2:1 ratio with target cells in medium without exogenous cytokines. After 72 h of incubation, cells were labeled with anti-CD8 / CD4 mAb and 7-AAD to exclude dead cells from the analysis. Samples were analyzed by flow cytometry, and viable T cell division was assessed by CFSE dilution. The cytolytic activity of CAR-modified and control T cells against primary AML cells was analyzed in a FACS-based cytotoxicity assay. T cells and AML cells were plated in 96-well plates and target cells at 10 × 10 per well. 3 The cells were seeded at effector:target (E:T) ratios ranging from 20:1 to 1:1. After 4–24 h, cultures were aspirated and stained with 7-AAD to distinguish live from dead cells and with anti-CD3 / anti-CD33 / anti-CD45 mAbs to distinguish T cells from AML cells. To quantify the number of remaining viable AML cells, 123-counting beads (e-bioscience, San Diego, CA) were used according to the manufacturer's instructions. Flow cytometry analysis was performed on a FACS Canto II (BD) and data were analyzed using FlowJo software (Treestar).

[0136] In vivo experiments All experiments were approved by the Institutional Animal Care and Use Committee of the participating institutions. scid Il2rg tm1Wjl / SzJ(NSG) mice (female, 6-8 weeks old) were purchased from Charles River or bred in-house. Mice were transfected with ffluc_GFP on day 0. + MOLM-13 AML cells 1×10 6 5 × 10 T cells were inoculated by tail vein injection on day 7. 6Mice were dosed with a single dose of 100 mg / kg (in 200 μL of PBS / 0.5% FCS) via tail vein injection. Crenolanib [15 mg / kg; 200 μL of 30% glycerol formal (Sigma Aldrich, Munich, Germany)] was administered intraperitoneally (i.p.) Monday through Friday for three consecutive weeks. After i.p. administration of D-luciferin substrate (0.3 mg / g body weight) (Biosynth, Staad, Switzerland), AML progression / regression was assessed by graded bioluminescence imaging using an IVIS Lumina imaging system (Perkin Elmer, Waltham, Massachusetts). Data were analyzed using Living Image software (Perkin Elmer).

[0137] Treatment of MOLM-13 AML cells with FLT3 inhibitors MOLM-13 were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 10 nM crenolanib or 1 nM quizartinib or 10 nM midostaurin. Complete medium changes were performed every 7 days, and MOLM-13 cells were cultured at 1 × 10 per mL of medium. 6 The cells were adjusted to 100 μg / well and 2 mL of this cell suspension was plated per well of a 48-well plate (Costar, Corning, NJ). After 2–3 weeks of culture with 10 nM midostaurin, MOLM-13 cells were exposed to exponentially increasing concentrations of midostaurin over the next 8–10 weeks until 50 nM midostaurin was reached.

[0138] Medicines and Reagents Crenolanib, quizartinib (Selleck Chemicals, Houston, TX), and midostaurin (Novartis, Basel, Switzerland / Selleck Chemicals, Houston, TX / Sigma-Aldrich, Steinheim, Germany) were reconstituted in dimethyl sulfoxide (DMSO) and then diluted in culture medium or 30% glycerol formal (Sigma Aldrich, Munich, Germany) for in vitro or in vivo experiments, respectively.

[0139] statistical analysis Statistical analysis was performed using Prism software v6.07 (GraphPad). Unpaired Student's t test was used to analyze data obtained in vitro. Log-rank (Mantel-Cox) test was performed to analyze survival differences observed in in vivo experiments. Differences with p values ​​<.05 were considered statistically significant.

[0140] result: FLT3 CAR-T cells were compared with FLT3 wild-type cells and FLT3-ITD cells. + Eliminate AML cells A CAR transgene containing a targeting domain derived from the FLT3-specific mAb BV10 was constructed and administered to CD4 + T cells and CD8 + Gene transfer into T cells was performed. FLT3 CAR-transduced T cells were enriched to >90% purity using the EGFRt transduction marker, followed by expansion and functional testing (Figure 26). First, native K562 (phenotype: FLT3 - ) and K562 target cells transduced to stably express wild-type FLT3 (K562 / FLT3) were used to generate CD4 + FLT3 CAR-T cells and CD8 +Specific recognition of the FLT3 surface protein by FLT3 CAR-T cells was confirmed (Figure 27). Next, AML cell lines THP-1 (FLT3 wild type), MOLM-13 (FLT3-ITD + / - ) and MV4;11(FLT3-ITD + / + ) were included in our analysis, and for each of the cell lines, CD8 + A specific high-level cytolytic activity of FLT3 CAR-T cells was confirmed (Figures 28A and 28B). + FLT3 CAR-T cells and CD8 + FLT3 CAR-T cells produced effector cytokines including IFN-γ and IL-2 and proliferated productively after stimulation with each of the AML cell lines, whereas control T cells from the same respective donors showed only background reactivity (Figures 29, 30). Because the FLT3 CAR binds to an epitope within the extracellular domain of FLT3, recognition of AML cells was independent of the mutational status of the intracellular tyrosine kinase domain, but instead correlated with the antigen density of FLT3 surface protein on target cells as assessed by mean fluorescence intensity (MFI) (THP-1 ~ MOLM-13>MV4;11) (Figure 28A).

[0141] FLT3-ITD in patient-derived FLT3 CAR-T cells + Potent activity against primary AML cells was also observed, with potent cytolytic activity leading to eradication of >80% of AML blasts in as little as 4 hours (E:T ranging from 20:1 to 1:1) (Figure 28A,B). Notably, the anti-leukemic activity of FLT3 CAR-T cells against primary AML blasts was comparable to T cells expressing a similarly engineered CAR specific for the alternative AML target antigen CD123 (Figure 28B).

[0142] FLT3 CAR-T cells induce durable AML remissions in vivo in a xenograft model Experiments were performed to analyze the function of FLT3 CAR-T cells in vivo in a xenograft model of AML in immunodeficient NSG mice. After inoculation with ffLuc_GFP-transduced MOLM-13 AML cells, mice rapidly developed systemic leukemia with leukemic cells circulating in the peripheral blood and infiltration of the bone marrow and spleen (Figure 31A). Leukemia-bearing mice were cultured in a 10-well plate with a comparable proportion of CD4 + T cells and CD8 + Consisting of T cells, FLT3 CAR modified T cells or non-transduced T cells 5 x 10 6 The mice were treated with a single dose of FLT3 CAR-T cells or were not treated. A strong anti-leukemic effect was confirmed in all mice that showed engraftment of FLT3 CAR-T cells. In these mice, the number of FLT3 CAR-T cells increased during the anti-leukemic response and could be easily detected in the peripheral blood at multiple time points, confirming their persistence beyond 3 weeks after adoptive transfer (Figure 31B). Stepwise bioluminescence imaging confirmed strong anti-leukemic activity in all mice engrafted with FLT3 CAR-T cells, whereas mice that failed to engraft CAR-T cells, mice treated with control T cells, and untreated mice showed rapid leukemia progression (Figures 31A, 32A). Further flow cytometry analysis confirmed sustained complete remission of AML cells derived from bone marrow and spleen (Figure 33A). Kaplan-Meier analysis showed significantly longer overall survival after treatment with FLT3 CAR-T cells compared to control T cells and no treatment (p<.05) (Figure 32B). All mice responded to FLT3 CAR-T cell therapy, consistent with previous reports of CAR-T cell therapy in the NSG mouse model. 37、43 Consistent with this, it is noteworthy that relapse of extramedullary late stage disease was also observed (Figure 31A). Expression of FLT3 in AML cells derived from extramedullary late stage disease manifestations was detectable at levels similar to native MOLM-13 cells, i.e., no antigen loss occurred. Overall, our data demonstrate that FLT3 CAR-T cells inhibit FLT3 wild-type and FLT3-ITD cells in vitro and in vivo. +It is shown to confer potent anti-leukemic activity against AML cell lines and primary AML cells.

[0143] Midostaurin is a treatment for FLT3-ITD + Induces increased FLT3 surface protein expression in AML cells FLT3-ITD + Findings from clinical trials in patients with AML are the upregulation of FLT3 as a compensatory mechanism in AML blasts to counteract the effects of FLT3 inhibitors, a mechanism that we hypothesize could be exploited to enhance the anti-leukemia efficacy of FLT3 CAR-T cells. 24、25 . Naive MOLM-13 AML cells (MOLM-13 Native )(FLT3-ITD + / - ) in combination with the FLT3 inhibitor midostaurin (MOLM-13 mido After 2–3 weeks of drug exposure, MOLM-13 mido FLT3 expression was analyzed by flow cytometry and as assessed by MFI in MOLM-13 native We indeed observed significantly higher levels of FLT3 surface protein compared to MOLM-13 cells (n=2 experiments, p<.05) (Figure 10A). Furthermore, we slowly increased the midostaurin concentration from 10 nM to 50 nM over the next 8-10 weeks and observed a further increase in FLT3 expression (Figure 10B). Interestingly, cessation of midostaurin led to a decline in FLT3 expression in MOLM-13 cells to baseline or slightly below baseline levels within 2 days, but it rose again upon re-exposure to the drug (Figure 10C). After primary exposure to midostaurin, MOLM-13 cells showed a significant increase in FLT3 expression over a period of approximately 2 weeks. native Compared with MOLM-13 cells mido A moderate cytotoxic effect and slower expansion of cells was observed. However, the cytotoxic effect of midostaurin subsequently disappeared, and MOLM-13 cells were not cultured despite continued supplementation of the culture medium. mido Cell proliferation was accelerated, which resulted in MOLM-13 mido It is shown that the cells had acquired resistance.

[0144] Increased FLT3 expression upon exposure to midostaurin was observed in MV4;11 AML cells (FLT3-ITD + / + ), but not in several cell lines expressing wild-type FLT3, i.e., THP-1 AML cells and K562 erythromyelogenous leukemia, suggesting that the upregulation of FLT3 expression in response to midostaurin treatment is due to the FLT3-ITD + This suggests that this occurs specifically in AML cells (FIGS. 10A and 10B).

[0145] AML MOLM-13 mido High FLT3 expression in cells leads to enhanced anti-leukemia reactivity of FLT3 CAR-T cells in vitro E:T ratio 10:1, native MOLM-13 native Compared with cells (79.4 ± 2.9), MOLM-13 mido Significantly higher CD8 + Cytolytic activity of FLT3 CAR-T cells was observed (90.3±1.9) (p<0.05) (Figure 34). Furthermore, CD8 + A 1.3-fold increase in cytolytic activity of FLT3 CAR-T cells (84.5±1.8 vs. 64.6±4.1 at an E:T ratio of 5:1) and a 1.6-fold increase (59.1±5.5 vs. 36.1±2.3 at an E:T ratio of 2.5:1) were observed (Figure 34). native MOLM-13 compared to cells mido We analyzed the specific cytokine production by FLT3 CAR-T cells against IL-13. In fact, FLT3-CAR T cells increased IFN-γ production by 2.1 times (MOLM-13 mido Against MOLM-13 native , 3079.0±153.0pg / mL vs. 1477.0±78.0pg / mL) and 6.6-fold increased IL-2 production (MOLM-13 mido Against MOLM-13 native , 1328.0±63.0 pg / mL vs. 202.0±41.0 pg / mL) was observed (Figure 35A). FLT3 CAR T cells outperformed native MOLM-13native Compared to cells, MOLM-13 mido The proliferation index was 1.8 times higher than that of the control (% proliferation, MOLM-13 mido Against MOLM-13 native , 75.1 vs. 41.2) (Figure 35B). mido The percentages of T cells that expanded at least four-fold and at least five-fold after stimulation with were 28.3 and 32.9, compared with MOLM-13. native for 13.4 and 15.1, respectively (FIG. 35B), demonstrating a significant gain of function.

[0146] Crenolanib is a treatment for FLT3-ITD + Induces increased FLT3 surface protein expression in AML cells FLT3-ITD + Findings from clinical trials in patients with AML are the upregulation of FLT3 as a compensatory mechanism in AML blasts to counteract the effects of FLT3 inhibitors, a mechanism that we hypothesize could be exploited to enhance the anti-leukemia efficacy of FLT3 CAR-T cells. 24、25 . Naive MOLM-13 AML cells (MOLM-13 native )(FLT3-ITD + / - ) was administered in combination with the FLT3 inhibitor crenolanib (MOLM-13) at a clinically achievable serum level of 10 nM. creno ) were cultured in the presence of 27、44 MOLM-13 cells were analyzed by flow cytometry 5 days after exposure to drugs. creno We analyzed FLT3 expression in MOLM-13 mice as assessed by MFI. native We indeed observed significantly higher levels of FLT3 surface protein compared to MOLM-13 cells (n=3 experiments, p<.05) (Figure 14A). Interestingly, cessation of crenolanib led to a decline in FLT3 expression in MOLM-13 cells to baseline levels within 2 days, but it rose again upon re-exposure to the drug (Figure 14B). After primary exposure to crenolanib, MOLM-13 cells were significantly higher for approximately 7 days. native Compared with MOLM-13 cellscreno A moderate cytotoxic effect and slower expansion of cells was observed. However, the cytotoxic effect of crenolanib subsequently disappeared, and MOLM-13 cells were not cultured despite continued supplementation of the culture medium. creno The proliferation of the cells was accelerated, suggesting that these cells had acquired resistance.

[0147] AML MOLM-13 creno High FLT3 expression in cells leads to enhanced anti-leukemia reactivity of FLT3 CAR-T cells in vitro E:T ratio 10:1, native MOLM-13 native Compared to cells (63.4 ± 5.3) MOLM-13 creno Significantly higher CD8 + Cytolytic activity of FLT3 CAR-T cells was observed (81.4±2.0) (p<0.05) (Figure 36). Furthermore, CD8 + A 1.6-fold increase in cytolytic activity of FLT3 CAR-T cells (67.0±2.4 vs. 41.9±9.0 at an E:T ratio of 5:1) and a 1.8-fold increase (56.8±1.8 vs. 30.5±4.7 at an E:T ratio of 2.5:1) were observed (Figure 36). native Compared with MOLM-13 cells creno We analyzed the specific cytokine production by FLT3 CAR-T cells against IL-13. In fact, FLT3-CAR T cells increased IFN-γ production by 1.6-fold (MOLM-13 creno Against MOLM-13 native , 2413.5±79.3pg / mL vs. 1477.1±110.4pg / mL) and 2.0-fold increased IL-2 production (MOLM-13 creno Against MOLM-13 native , 642.0±177.1 pg / mL vs. 317.6±105.7 pg / mL) were observed (Figure 37A). FLT3 CAR T cells outperformed native MOLM-13 native Compared with MOLM-13 cells creno The proliferation index was 1.3 times higher than that of the control (% proliferation, MOLM-13 creno Against MOLM-13 native, 73.0 vs. 56.5) (Figure 37B). creno The percentages of T cells that expanded at least four-fold and at least five-fold after stimulation with IL-13 were 16.6 and 25.2, compared with MOLM-13. native 9.5 and 17.3, respectively (FIG. 37B), demonstrating a significant gain of function.

[0148] Quizartinib midostaurin is a treatment for FLT3-ITD + Induces increased FLT3 surface protein expression in AML cells FLT3-ITD + Findings from clinical trials in patients with AML are the upregulation of FLT3 as a compensatory mechanism in AML blasts to counteract the effects of FLT3 inhibitors, a mechanism that we hypothesize could be exploited to enhance the anti-leukemia efficacy of FLT3 CAR-T cells. 24、25 . Naive MOLM-13 AML cells (MOLM-13 native )(FLT3-ITD + / - ) in combination with the FLT3 inhibitor quizartinib (MOLM-13) at a clinically achievable serum level of 1 nM. Quiza ) were cultured in the presence of 27、44 MOLM-13 cells were analyzed by flow cytometry 5 days after exposure to drugs. quiza We analyzed FLT3 expression in MOLM-13 mice as assessed by MFI. native We indeed observed significantly higher levels of FLT3 surface protein compared to MOLM-13 cells (n=3 experiments, p<.05) (Figure 19A). Interestingly, cessation of quizartinib led to a decline in FLT3 expression in MOLM-13 cells to baseline levels within 2 days, but it rose again upon re-exposure to the drug (Figure 19B). After primary exposure to quizartinib, MOLM-13 cells were significantly higher for approximately 7 days. native Compared with MOLM-13 cells quiza A moderate cytotoxic effect and slower expansion of cells was observed. However, the cytotoxic effect of quizartinib subsequently disappeared, despite continued supplementation of the culture medium, and MOLM-13quiza The proliferation of the cells was accelerated, suggesting that these cells had acquired resistance.

[0149] Increased FLT3 expression upon exposure to quizartinib was observed in MV4;11 AML cells (FLT3-ITD + / + ), but not in several cell lines expressing wild-type FLT3, i.e., THP-1 AML cells, JeKo-1 mantle cell lymphoma, and K562 erythromyeloid leukemia, suggesting that upregulation of FLT3 expression in response to quizartinib treatment is consistent with FLT3-ITD. + This suggests that this occurs specifically in AML cells (FIG. 19B).

[0150] AML MOLM-13 quiza High FLT3 expression in cells leads to enhanced anti-leukemia reactivity of FLT3 CAR-T cells in vitro E:T ratio 10:1, native MOLM-13 native Cells (54.4 ± 1.7) compared with MOLM-13 quiza (72.4±3.9) compared with a significantly higher CD8 + Cytolytic activity of FLT3 CAR-T cells was observed (p<0.05) (Figure 38). Furthermore, CD8 + A 1.6-fold increase (42.6±3.9 vs. 27.0±5.6 at an E:T ratio of 5:1) and a 3.8-fold increase (24.9±4.5 vs. 6.6±7.0 at an E:T ratio of 2.5:1) in the cytolytic activity of FLT3 CAR-T cells was observed (Figure 38). native Compared with MOLM-13 cells quiza We analyzed the specific cytokine production by FLT3 CAR-T cells against IL-13. In fact, FLT3-CAR T cells produced 1.2-fold more IFN-γ than IL-13. quiza Against MOLM-13 native , 1839.0±11.0pg / mL vs. 1477.0±78.0pg / mL) and 1.9-fold increased IL-2 production (MOLM-13 quiza Against MOLM-13 native, 376.0±10.0 pg / mL vs. 202.0±41.0 pg / mL) were observed (Figure 39A). FLT3 CAR T cells outperformed native MOLM-13 native Compared with MOLM-13 cells quiza (% proliferation, MOLM-13 quiza Against MOLM-13 native MOLM-13 proliferated 1.2-fold (proliferation index) greater than that of the control (65.0 vs. 56.5) (Figure 39B). quiza The percentages of T cells that expanded at least four-fold and at least five-fold after stimulation with IL-13 were 14.2 and 22.5, compared with MOLM-13. native 9.5 and 17.3, respectively, for (FIG. 39B), demonstrating a significant gain of function.

[0151] Example 3 Materials and Methods: Human subjects Peripheral blood was obtained from healthy donors after written informed consent for participation in a study protocol approved by the Institutional Review Board of Wurzburg.

[0152] Tumor cell lines The human leukemia cell line MOLM-13 (ACC 554) was purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) and cultured in RPMI-1640 supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and 100 U / mL penicillin / streptomycin. MOLM-13 cells were transduced with a lentiviral vector encoding a firefly luciferase (ffluc)_green fluorescent protein (GFP) transgene to allow detection by flow cytometry (GFP) and bioluminescence imaging in mice (ffLuc), and bioluminescence-based cytotoxicity assays.

[0153] Flow cytometry analysis of FLT3 expression Cell surface FLT3 expression was analyzed using a conjugated mouse anti-human FLT3 mAb (clone 4G8, BD Biosciences, Germany) and a mouse IgG1 isotype control (BD). Briefly, 1 × 10 cells were cultured at 4 °C for 1 h. 6 The cells were washed, resuspended in 100 μL PBS / 0.5% fetal bovine serum, and stained with 5 μL anti-FLT3 mAb or isotype for 30 min at 4°C.

[0154] CAR construction FLT3-specific BV10 mAb 12 V H Segment and V L A codon-optimized targeting domain containing the segment was synthesized (GeneArt, ThermoFisher, Regensburg, Germany) and fused in-frame to a CAR scaffold containing a short IgG4-Fc hinge spacer, a CD28 transmembrane and costimulatory portion, and a CD3z, T2A element, and an EGFRt transduction marker (Figure 1). 32~34 The entire transgene was encoded in the lentiviral vector epHIV7 and expressed under the control of the EF1 / HTLV hybrid promoter. 34、35 .

[0155] Preparation of CAR-modified T cells CD4 activated with CD3 / 28 beads (ThermoFisher) + T cells and CD8 + Lentiviral gene transfer into T cells was performed 1 day after bead stimulation at an MOI of 5. T cells were cultured in RPMI-1640 supplemented with 10% human serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 50 U / mL recombinant human interleukin (IL)-2 (Proleukine, Novartis, Basel, Switzerland). 32CAR-transduced T cells were enriched using biotinylated anti-EGFR mAb (ImClone Systems Inc.) and anti-biotin beads (Miltenyi) and then expanded using a rapid expansion protocol. 38 .

[0156] Flow cytometric analysis of T cells CAR-modified and non-transduced T cells were stained with one or more of the following conjugated mAbs: CD3, CD4, CD8 and 7-AAD for live / dead cell discrimination (Miltenyi / BD / Biolegend). + ) T cells were detected by staining with an in-house biotinylated anti-EGFR antibody (EZ-Link™ Sulfo-NHS-SS-Biotin, Thermofisher Scientific, IL, according to manufacturer's instructions) and streptavidin-PE. Flow analysis was performed on a FACSCanto (BD), and data were analyzed using FlowJo software v9.0.2 (Treestar, Ashland, OR).

[0157] In vivo experiments All experiments were approved by the Institutional Animal Care and Use Committee of the participating institutions. scid Il2rg tm1Wjl / SzJ(NSG) mice (female, 6-8 weeks old) were purchased from Charles River or bred in-house. Mice were transfected with ffluc_GFP on day 0. + MOLM-13 AML cells 1×10 6 5 × 10 T cells were inoculated by tail vein injection on day 7. 6Mice were dosed with a single dose of 100 mg / kg (in 200 μL of PBS / 0.5% FCS) via tail vein injection. Quizartinib [1 mg / kg; 200 μL of 30% glycerol formal] or midostaurin [1 mg / kg; 200 μL of 30% glycerol formal] were administered intraperitoneally (ip) Monday through Friday for three consecutive weeks (total of 15 doses). After ip administration of D-luciferin substrate (0.3 mg / g body weight) (Biosynth, Staad, Switzerland), AML progression / regression was assessed by graded bioluminescence imaging using an IVIS Lumina imaging system (Perkin Elmer, Waltham, Massachusetts). Data were analyzed using Living Image software (Perkin Elmer).

[0158] Medicines and Reagents Quizartinib and midostaurin (Selleck Chemicals, Houston, TX) were reconstituted in dimethyl sulfoxide (DMSO) and then diluted in 30% glycerol formal (Sigma Aldrich, Munich, Germany) at the dilution used for in vivo experiments.

[0159] statistical analysis Statistical analysis was performed using Prism software v6.07 (GraphPad). Unpaired Student's t-test was used to analyze data. Log-rank (Mantel-Cox) test was performed to analyze survival differences observed in in vivo experiments. Differences with p-values ​​<.05 were considered statistically significant.

[0160] result: Midostaurin acts synergistically with FLT3 CAR-T cells in vivo We investigated the in vivo anti-leukemia effect of the combination of FLT3 CAR-T cells and midostaurin. NativeMice were inoculated with AML cells and treated with FLT3 CAR-T cells alone, midostaurin alone, FLT3 CAR-T cells and midostaurin combination treatment, or left untreated. The combination treatment was administered on two different schedules: one group of mice received midostaurin already from day 3 after leukemia inoculation (FLT3 CAR+early midostaurin, i.e., midostaurin administration started even before FLT3 CAR-T cell transfer), and the other group of mice received midostaurin from day 7 after leukemia inoculation (FLT3 CAR+midostaurin, i.e., midostaurin administration started on the day of FLT3 CAR-T cell transfer). In both groups, midostaurin was administered a total of 15 times.

[0161] Strong anti-leukemia efficacy was observed in mice treated with the combination of FLT3 CAR-T cells and midostaurin (Fig. 40a, b). Superior engraftment and in vivo expansion of FLT3 CAR-T cells was observed in mice receiving the combination therapy compared to mice treated with FLT3 CAR-T cells alone (Fig. 41a). The mean frequency of FLT3 CAR-T cells in mice receiving FLT3 CAR-T cells + midostaurin more than doubled (>100% increase) compared to mice receiving FLT3 CAR-T cells alone (p<0.05).

[0162] Furthermore, mice treated with the combination therapy showed faster and deeper remissions as assessed by bioluminescence imaging (Figure 40b). In the group of mice that received only midostaurin, no reduction in leukemia burden was observed in any of the mice (response rate: 0 / 4=0%). In the group of mice that received only FLT3 CAR-T cells, leukemia reduction was observed in all of the mice (4 / 4=100%), but the BL signal (as a marker of leukemia regression) was not reduced by more than 50-fold in any of the mice (0 / 4 mice=0%). In the group of mice that received FLT3 CAR-T cells + early midostaurin, leukemia reduction was observed in all of the mice (4 / 4=100%), with leukemia regressing by more than 50-fold in 3 out of 4 mice = 75% of the mice. In the group of mice that received FLT3 CAR-T cells + midostaurin, leukemia reduction was observed in all of the mice (4 / 4 = 100%), with 4 out of 4 = 100% of the mice experiencing greater than 50-fold regression of leukemia. The strongest anti-leukemia response was observed in the group of mice that received FLT3 CAR-T cells + midostaurin.

[0163] We analyzed FLT3 expression in MOLM-13 cells recovered from bone marrow and found that FLT3 was strongly upregulated in mice that received midostaurin compared to mice that did not receive midostaurin (Figure 41b). Notably, the MFI in mice with the lowest levels of FLT3 expression was 30% higher in the group of mice that received midostaurin compared to mice that did not receive midostaurin.

[0164] In summary, the data indicate that midostaurin exerts synergistic anti-leukemic activity in combination with FLT3 CAR-T cells.

[0165] Quizartinib acts synergistically with FLT3 CAR-T cells in vivo We investigated the anti-leukemic efficacy of the combination of FLT3 CAR-T cells and quizartinib in vivo in an NSG / MOLM-13 xenograft model. Mice were treated with a single dose of FLT3 CAR-T cells alone, quizartinib alone (1 mg / kg, ip), the FLT3 CAR-T cell and quizartinib combination treatment, or were left untreated.

[0166] Strong anti-leukemia efficacy was observed in mice treated with the combination of FLT3 CAR-T cells and quizartinib (Fig. 42a, b). Superior engraftment and significantly higher in vivo expansion of FLT3 CAR-T cells was observed in mice treated with the combination of quizartinib and LT3 CAR-T cells compared to mice treated with CAR-T cells alone (Fig. 43a). The mean frequency of FLT3 CAR-T cells in mice receiving FLT3 CAR-T cells + quizartinib was nearly doubled (>85% expansion) compared to mice receiving FLT3 CAR-T cells alone (p<0.0001).

[0167] Furthermore, mice treated with the combination therapy showed faster and deeper remissions as assessed by bioluminescence imaging (Figure 42b). In the group of mice that received only Quizartinib, no reduction in leukemic burden was observed in any of the mice (response rate: 0 / 4 = 0%). In the group of mice that received only FLT3 CAR-T cells, leukemia reduction was observed in all mice (6 / 6 = 100%), but 2 of the mice showed a greater than 20-fold reduction in BL signal (as a marker of leukemia regression) (2 / 6 mice = 33%). In the group of mice that received FLT3 CAR-T cells + Quizartinib, leukemia reduction was observed in all mice (6 / 6 = 100%), with 5 of 6 = 83.3% of mice showing greater than 20-fold regression of leukemia. The most potent anti-leukemia response was observed in the group of mice that received FLT3 CAR-T cells + Quizartinib.

[0168] FLT3 expression was analyzed in MOLM-13 cells recovered from bone marrow, and increased FLT3 expression was observed after quizartinib treatment (Figure 43b). Notably, the MFI in mice with the lowest levels of FLT3 expression was approximately 65% ​​higher in mice that received quizartinib compared to mice that did not receive quizartinib.

[0169] In summary, the data indicate that quizartinib acts synergistically in combination with FLT3 CAR-T cells in mediating leukemia regression in vivo.

[0170] Example 4 Human subjects Peripheral blood was obtained from healthy donors after written informed consent for participation in a study protocol approved by the Institutional Review Board of Wurzburg.

[0171] Tumor cell lines Human leukemia cell lines NALM-16 (ACC 680), KOPN-8 (ACC 552), and SEM (ACC 546) were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) and cultured in RPMI-1640 supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and 100 U / mL penicillin / streptomycin. All cell lines were transduced with lentiviral vectors encoding firefly luciferase (ffluc)_green fluorescent protein (GFP) transgenes to allow detection by flow cytometry (GFP) and bioluminescence imaging in mice (ffLuc), and bioluminescence-based cytotoxicity assays.

[0172] Flow cytometry analysis of FLT3 expression Cell surface FLT3 expression (CD135) was analyzed using a conjugated mouse anti-human FLT3 mAb (clone 4G8, BD Biosciences, Germany) and a mouse IgG1 isotype control (BD). 6 The cells were washed, resuspended in 100 μL PBS / 0.5% fetal bovine serum, and stained with 5 μL anti-FLT3 mAb or isotype for 30 min at 4°C.

[0173] CAR construction FLT3-specific BV10 mAb12 V H Segment and V L A codon-optimized targeting domain containing the segment was synthesized (GeneArt, ThermoFisher, Regensburg, Germany) and fused in-frame to a CAR scaffold containing a short IgG4-Fc hinge spacer, a CD28 transmembrane and costimulatory portion, and a CD3z, T2A element, and an EGFRt transduction marker (Figure 1). 32~34 The entire transgene was encoded in the lentiviral vector epHIV7 and expressed under the control of the EF1 / HTLV hybrid promoter. 34、35 Similarly, CD19 was generated using a targeting domain specific for CD19 (clone FMC63). 32、33、36、37 .

[0174] Preparation of CAR-modified T cells CD4 activated with CD3 / 28 beads (ThermoFisher) + T cells and CD8 + Lentiviral gene transfer into T cells was performed 1 day after bead stimulation at a multiplicity of infection (MOI) of 5. T cells were cultured in RPMI-1640 supplemented with 10% human serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 50 U / mL recombinant human interleukin (IL)-2 (Proleukiine, Novartis, Basel, Switzerland). 32CAR-transduced T cells were enriched using biotinylated anti-EGFR mAb (ImClone Systems Inc.) and anti-biotin beads (Miltenyi), followed by a rapid expansion protocol. 38 or for CD19 CAR-T cells, irradiated (80 Gy) CD19 + Expanded using antigen-specific stimulation with feeder cells 38 .

[0175] Flow cytometric analysis of T cells CAR-modified and non-transduced T cells were stained with one or more of the following conjugated mAbs for live / dead cell discrimination: CD3, CD4, CD8 and 7-AAD (Miltenyi / BD / Biolegend). + ) T cells were detected by staining with an in-house biotinylated anti-EGFR antibody (EZ-Link™ Sulfo-NHS-SS-Biotin, Thermofisher Scientific, IL, according to manufacturer's instructions) and streptavidin-PE. Flow analysis was performed on a FACSCanto (BD), and data were analyzed using FlowJo software v9.0.2 (Treestar, Ashland, OR).

[0176] Analysis of CAR-T cell function in vitro Functional assays were performed as previously described 32、33、39~41 Briefly, target cells expressing firefly luciferase (ffLuc) were plated at 5 × 10 cells per well. 3Target cells were incubated in triplicate with effector T cells at various effector to target (E:T) ratios. After 4 h of incubation, luciferin substrate was added to the co-cultures and the reduction in luminescence signal in wells containing target and T cells was measured using a luminometer (Tecan, Mannedorf, Switzerland) and compared to target cells alone. Specific lysis was calculated using the standard formula: 42 To analyze cytokine secretion, 50 x 10 T cells were 3 50 × 10 T cells were plated in triplicate wells at a 2:1 ratio with target cells and incubated for 24 h before measuring IFN-γ and IL-2 production in the supernatants by ELISA (Biolegend). 3 T cells were labeled with 0.2 μM carboxyfluorescein succinimidyl ester (CFSE, ThermoFisher), washed, and plated in triplicate wells at a 2:1 ratio with target cells in medium without exogenous cytokines. After 72 h of incubation, cells were labeled with anti-CD8 / CD4 mAb and 7-AAD to exclude dead cells from the analysis. Samples were analyzed by flow cytometry, and viable T cell division was assessed by CFSE dilution.

[0177] Treatment of leukemia cells with FLT3 inhibitors Acute lymphoblastic leukemia (NALM-16) and mixed lineage leukemia (KOPN-8 and SEM) cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 10 nM crenolanib or 1 nM quizartinib or 50 nM midostaurin. 1 × 10 cells per mL were cultured. 6 NALM-16 cell suspension, KOPN-8 cell suspension, and SEM cell suspension were plated per well of a 24-well plate (Costar, Corning, NJ). After 1 week of culture with 10 nM crenolanib, 1 nM quizartinib, or 50 nM midostaurin, the cells were stained with anti-FLT3 4G8 mAb and subjected to flow cytometry analysis.

[0178] Medicines and Reagents Crenolanib, quizartinib and midostaurin (Selleck Chemicals, Houston, TX) were reconstituted in dimethyl sulfoxide (DMSO) and then diluted in culture medium or 30% glycerol formal (Sigma Aldrich, Munich, Germany) for in vitro or in vivo experiments, respectively.

[0179] statistical analysis Statistical analysis was performed using Prism software v6.07 (GraphPad). Unpaired Student's t test was used to analyze data obtained from in vitro experiments. Differences with p values ​​<.05 were considered statistically significant.

[0180] result: FLT3 CAR-T cells mediate potent anti-leukemic activity against ALL and MLL in vitro FLT3 expression has been reported in patients with acute lymphoblastic leukemia (ALL) and mixed lineage leukemia (MLL) 1、4、47 Therefore, we sought to determine whether FLT3 CAR-T cells could recognize and eliminate ALL and MLL.

[0181] To evaluate the reactivity of FLT3 CAR-T cells against ALL and MLL cell lines, NALM-16 (wt FLT3+, CD19+ pediatric ALL), KOPN-8 (wt FLT3+, CD19+ infantile MLL with KMT2A-MLLT1 fusion gene) and SEM (wt FLT3+, CD19+ pediatric MLL with KMT2A-AFF1 fusion gene) were included in our analysis. First, FLT3 expression in all three cell lines was confirmed using flow cytometry (Figure 44a). Functional analysis was then performed, demonstrating that FLT3 expression was upregulated by CD8+ at multiple effector-to-target cell ratios (range: 10:1-2.5:1) against all three cell lines. + A high level of specific cytolytic activity of FLT3 CAR-T cells was observed (Figure 44b).+ FLT3 and CD19 CAR-T cells produced significant amounts of IL-2 and proliferated in an antigen-specific manner following stimulation with all three target cell lines, whereas control T cells did not show any proliferation (Fig. 45a, b).

[0182] Next, we analyzed whether FLT3 expression in ALL cells and MLL cells can be enhanced by treatment with FLT3 inhibitors.Therefore, ALL cells and MLL cells expressing wild-type FLT3 were exposed to FLT3 inhibitors for 7 days.However, no increase in FLT3 expression was observed in these cells within the assay period (Figure 46a).

[0183] In summary, the results indicate that FLT3 CAR-T cells exert specific anti-leukemic activity against FLT3-positive ALL and MLL and can be utilized for the treatment of ALL and MLL patients.

[0184] The fact that no increase in FLT3 expression was observed in FLT3 wild-type cells within the assay period after treatment with the tested FLT3 inhibitors (Figure 46a) does not exclude the possibility that an increase in FLT3 expression occurs in wild-type FLT3 expressing cancers after long-term treatment with FLT3 inhibitors (as seen in CEP701). 24Indeed, considering that wild-type FLT3 is known to be highly expressed in some cancers, it is expected that treatment of cancers expressing wild-type FLT3 with FLT3 inhibitors will lead to long-term adaptation (e.g., by genetic selection) of the cancer cells to counteract FLT3 inhibition by a mechanism that involves further increasing wild-type FLT3 expression. According to the present invention, treatment with FLT3-targeting agents (e.g., cells modified with CARs, such as CAR-T cells) is particularly effective in cancers that exhibit (further) increased wild-type FLT3 expression. Thus, it is expected that combination treatment with kinase inhibitors according to the present invention (e.g., FLT3 inhibitors according to the present invention) and FLT3-targeting agents according to the present invention (e.g., cells modified with CARs, such as CAR-T cells) will be effective in cancers expressing wild-type FLT3, and will show synergistic effects of the kinase inhibitor and the FLT3-targeting agent. Furthermore, it is also expected that said combination treatment according to the present invention will be effective to prevent or effectively treat situations in which cancers expressing wild-type FLT3 acquire FLT3 mutations during the course of treatment with FLT3 inhibitors.

[0185] Thus, the present invention may be advantageously applied to cancer, including any cancer that expresses wild-type FLT3 and / or mutant FLT3.

[0186] Example 5 Human subjects Peripheral blood was obtained from healthy donors after written informed consent for participation in a study protocol approved by the Institutional Review Board of Wurzburg.

[0187] Treatment of MV4;11 AML cells with FLT3 inhibitors MV4;11 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U / mL penicillin / streptomycin, and 10 nM crenolanib or 1 nM quizartinib or 50 nM midostaurin. MV4;11 cells were grown at 1 × 10 per mL in 1 mL per well of a 24-well plate (Costar, Corning, NJ). 6 The cells were plated at a concentration of 100 mM.

[0188] Antibody-dependent cellular cytotoxicity (ADCC) assay MV4;11 AML cells transduced with firefly luciferase (ffluc) were utilized for the ADCC assay. MV4;11 AML cells were pretreated with FLT3 inhibitors for 7 days or left untreated. Target cells were co-incubated with PBMCs from healthy donors at an effector to target ratio of 50:1 in triplicate wells of 96-well flat-bottom plates in the presence of vehicle control, IgG1 isotype control (5000 ng / mL) or anti-FLT3 BV10 mAb (5000 ng / mL) (Biolegend, London, UK). ADCC was determined after 24 hours in a bioluminescence-based assay. 40 Luciferin substrate was added to the co-cultures and the reduction in luminescence signal was measured using a luminometer (Tecan, Mannedorf, Switzerland). The percentage of viable cells was calculated using the following formula: % viability = bioluminescence signal in the presence of effector cells and BV10 mAb (with or without pretreatment with FLT3 inhibitor) × 100 / bioluminescence signal under control conditions.

[0189] Medicines and Reagents Crenolanib, quizartinib and midostaurin (Selleck Chemicals, Houston, TX) were reconstituted in dimethyl sulfoxide (DMSO) and then diluted in culture medium for use in in vitro experiments.

[0190] statistical analysis Statistical analysis was performed using Prism software v6.07 (GraphPad). Unpaired Student's t test was used to analyze data obtained from in vitro experiments. Differences with p values ​​<.05 were considered statistically significant.

[0191] result: FLT3 inhibitors act synergistically with anti-FLT3 mAbs We attempted to determine whether the increased FLT3 antigen density of AML cells following treatment with FLT3 inhibitors would allow for superior anti-FLT3 mAb anti-leukemic activity. Therefore, MV4;11 AML cells were treated with FLT3 inhibitors (10 nM crenolanib, 1 nM quizartinib or 50 nM midostaurin) for 7 days. ADCC assays were then performed using anti-FLT3 mAb BV10. The corresponding isotype antibodies served as controls. MV4;11 target cells (untreated or FLT3 inhibitor-treated) and PBMCs from healthy donors were co-cultured in the presence or absence of BV10 mAb, and the reduction in viable MV4;11 cells was determined after 24 hours. A significant increase in ADCC was observed for MV4;11 cells treated with FLT3 inhibitors compared to untreated MV4;11 cells (Figure 47). On average, 39% of MV4;11 cells treated with crenolanib, 46% of MV4;11 cells treated with quizartinib, and 26% of MV4;11 cells treated with midostaurin were eliminated by BV10 mAb within the 24 hour ADCC assay, whereas only 13% of MV4;11 cells without FLT3 inhibitor pretreatment were eliminated (p<0.05) (Figure 47). These data indicate that the percentage of MV4;11 cells eliminated within the 24 hour assay period tripled after crenolanib pretreatment (39% vs. 13%), 3.5-fold after quizartinib pretreatment (46% vs. 13%), and doubled after midostaurin pretreatment (26% vs. 13%). In summary, the data indicate that FLT3 inhibitors exert synergistic anti-leukemic activity in combination with anti-FLT3 mAbs. [Industrial Applicability]

[0192] The inhibitors and targeting agents, their combinations, compositions and formulations, and kits according to the present invention can be industrially manufactured and sold as products for the claimed methods and uses (e.g., for the treatment of cancer as defined herein) in accordance with known standards for the manufacture of pharmaceutical products. Thus, the present invention has industrial applicability.

[0193] [References] 1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100(5): 1532-1542. 2. Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte / macrophage progenitor stages to maintain cell survival. The Journal of Immunology 2008; 180(11): 7358-7367. 3. Boiers C, Buza-Vidas N, Jensen CT, Pronk CJ, Kharazi S, Wittmann L, et al. Expression and role of FLT3 in regulation of the earliest stage of normal granulocyte-monocyte progenitor development. Blood 2010; 115(24): 5061-5068. 4. Rosnet O, Buhring H, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3 / FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996; 10(2): 238-248. 5. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. Journal of Experimental Medicine 2003; 198(2): 305-313. 6. Park I-K, Trotta R, Yu J, Caligiuri MA. Axl / Gas6 pathway participates in human natural killer cell development by positively regulating FLT3 activation. European journal of immunology 2013; 43(10). 7. Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nature immunology 2008; 9(6): 676-683. 8. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1 / Flk2) in human leukemias. Blood 1996; 87(3): 1089-1096. 9. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103(5): 1901-1908. 10. Vora HH, Shukla SN, Brahambhatt BV, Mehta SH, Patel NA, Parikh SK, et al. Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia. Asia‐Pacific Journal of Clinical Oncology 2010; 6(4): 306-319. 11. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116(24): 5089-5102. 12. Hofmann M, Grobe-Hovest L, Nubling T, Pyz E, Bamberg M, Aulwurm S, et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia 2012; 26(6): 1228-1237. 13. Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology 2012; 1(6): 863-873. 14. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 2005; 90(12): 1617-1625. 15. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99(12): 4326-4335. 16. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer cell 2007; 12(6): 501-513. 17. Levis M, Murphy KM, Pham R, Kim K-T, Stine A, Li L, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005; 106(2): 673-680. 18. Shih L, Huang C, Wang P, Wu J, Lin T, Dunn P, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18(3): 466-475. 19. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. Journal of Clinical Oncology 2012; 30(7): 735-741. 20. Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood 2015; 126(17): 2062-2069. 21. Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. International journal of hematology 2013; 97(6): 683-694. 22. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia‐Manero G, et al. Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 2014; 120(14): 2142-2149. 23. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede M, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107(1): 293-300. 24. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006; 108(10): 3262-3270. 25. Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, et al. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PloS one 2011; 6(9): e25351. 26. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proceedings of the National Academy of Sciences 2014; 111(14): 5319-5324. 27. Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD - positive acute myeloid leukemia. Blood 2013; 122(22): 3607-3615. 28. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clinical Cancer Research 2012; 18(16): 4375-4384. 29. Wetmore C, Broniscer A, Turner D, Wright KD, Pai-Panandiker A, Kun LE, et al. First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG). Journal of Clinical Oncology 2014; 32(15_suppl): 10064-10064. 30. Randhawa JK, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, et al. Results of a phase II study of crenolanib in relapsed / refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations. Blood 2014; 124(21): 389-389. 31. Cortes J. Results from a Phase II Study of Crenolanib in Patients With FLT3-Positive Acute Myeloid Leukemia. ASCO Annual Meeting 2016. 32. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer immunology research 2015; 3(2): 125-135. 33. Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clinical Cancer Research 2013; 19(12): 3153-3164. 34. Wang X, Chang W-C, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118(5): 1255-1263. 35. Yam PY, Li S, Wu J, Hu J, Zaia JA, Yee J-K. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Molecular Therapy 2002; 5(4): 479-484. 36. Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia 2017; 31(1): 186-194. 37. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014; 123(15): 2343-2354. 38. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. Journal of immunological methods 1990; 128(2): 189-201. 39. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010; 116(22): 4532-4541. 40. Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang W-C, Olivares S, et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. Journal of immunological methods 2005; 297(1): 39-52. 41. Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia 2016. 42. Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. Journal of immunological methods 2005 Feb; 297(1-2): 39-52. 43. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research 2007; 13(18): 5426-5435. 44. Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014; 123(1): 94-100. 45. Chen J, Schmitt A, Chen B, Rojewski M, Rubeler V, Fei F, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. Journal of cellular and molecular medicine 2008; 12(5b): 2107-2118. 46. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Experimental hematology 2008; 36(10): 1297-1308. 47. Negi S, Small D, Brown P. Level of FLT3 Expression in Leukemia Cells Correlates with Specific Histone Modifications and the Presence or Absence of MLL Fusion Genes, Implicating Epigenetic Regulation of FLT3 Expression. Blood 2008; 112(11): 4469.

Claims

[Claim 1] 1. A composition for use in a method for treating cancer in a patient, comprising: (a) a kinase inhibitor, and (b) FLT3 targeting drug Including, A composition administered to a patient in the method.